# Freetown

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 10 | 9.7 | 103.2 | (49.4-189.9) |  | Male | 3 | 6.4 | nc | (nc-nc) |
| Female | 2 | 2.9 | nc | (nc-nc) |  | Female | 4 | 4.5 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 2 | 2.0 | nc | (nc-nc) |  | Male | 2 | 2.1 | nc | (nc-nc) |
| Female | 1 | 1.5 | nc | (nc-nc) |  | Female | 3 | 1.4 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  | Male | 4 | 5.8 | nc | (nc-nc) |
| Female | 43 | 37.6 | 114.3 | (82.7-154.0) |  | Female | 5 | 4.3 | 117.1 | (37.7-273.3) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 7 | 5.1 | 137.2 | (55.0-282.6) |
| Female | 3 | 1.3 | nc | (nc-nc) |  | Female | 4 | 1.9 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 12 | 10.8 | 110.8 | (57.2-193.6) |  |  |  |  |  |  |
| Female | 3 | 8.4 | nc | (nc-nc) |  | Female | 2 | 3.1 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 1 | 2.7 | nc | (nc-nc) |  | Male | 0 | 3.6 | nc | (nc-nc) |
| Female | 0 | 0.6 | nc | (nc-nc) |  | Female | 5 | 2.9 | 174.6 | (56.3-407.5) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 1 | 0.8 | nc | (nc-nc) |  | Male | 42 | 33.9 | 124.1 | (89.4-167.7) |
| Female | 0 | 0.6 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 5 | 5.9 | 85.0 | (27.4-198.5) |  | Male | 3 | 2.4 | nc | (nc-nc) |
| Female | 2 | 2.9 | nc | (nc-nc) |  | Female | 1 | 1.1 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 1 | 1.5 | nc | (nc-nc) |  | Male | 0 | 1.3 | nc | (nc-nc) |
| Female | 0 | 0.4 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 2 | 4.0 | nc | (nc-nc) |  | Male | 2 | 2.7 | nc | (nc-nc) |
| Female | 2 | 2.4 | nc | (nc-nc) |  | Female | 6 | 7.3 | 81.8 | (29.9-178.1) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 2 | 3.7 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 1 | 1.0 | nc | (nc-nc) |  | Female | 10 | 8.5 | 117.3 | (56.1-215.7) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 16 | 17.6 | 90.7 | (51.8-147.3) |  | Male | 127 | 132.3 | 96.0 | (80.0-114.2) |
| Female | 27 | 15.8 | 171.0 | (112.6-248.8) |  | Female | 138 | 119.1 | 115.9 | (97.4-136.9) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

112

# Gardner

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 14 | 22.1 | 63.2 | (34.5-106.1) |  | Male | 5 | 14.1 | 35.6 | (11.5-83.0) |
| Female | 11 | 8.2 | 133.6 | (66.6-239.1) |  | Female | 8 | 10.9 | 73.4 | (31.6-144.7) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 3 | 4.3 | nc | (nc-nc) |  | Male | 3 | 4.5 | nc | (nc-nc) |
| Female | 6 | 3.5 | 171.9 | (62.8-374.2) |  | Female | 3 | 3.7 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 1 | 0.7 | nc | (nc-nc) |  | Male | 10 | 12.7 | 78.9 | (37.8-145.1) |
| Female | 65 | 85.7 | 75.8 | (58.5-96.7) |  | Female | 11 | 11.3 | 97.2 | (48.4-173.9) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 13 | 10.2 | 127.4 | (67.8-217.9) |
| Female | 0 | 2.9 | nc | (nc-nc) |  | Female | 4 | 4.7 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 27 | 24.0 | 112.7 | (74.2-164.0) |  |  |  |  |  |  |
| Female | 23 | 23.8 | 96.5 | (61.2-144.8) |  | Female | 9 | 7.5 | 120.6 | (55.0-228.9) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 13 | 5.6 | 233.9 | (124.4-399.9) |  | Male | 8 | 7.8 | 102.8 | (44.3-202.6) |
| Female | 2 | 1.6 | nc | (nc-nc) |  | Female | 7 | 8.4 | 83.6 | (33.5-172.2) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 2 | 1.8 | nc | (nc-nc) |  | Male | 43 | 64.7 | 66.5 | (48.1-89.6) |
| Female | 2 | 1.3 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 15 | 12.0 | 124.6 | (69.7-205.6) |  | Male | 3 | 5.3 | nc | (nc-nc) |
| Female | 7 | 7.0 | 100.5 | (40.3-207.2) |  | Female | 4 | 3.3 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 2 | 3.2 | nc | (nc-nc) |  | Male | 3 | 3.3 | nc | (nc-nc) |
| Female | 1 | 0.9 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 11 | 9.0 | 122.1 | (60.9-218.4) |  | Male | 2 | 5.7 | nc | (nc-nc) |
| Female | 10 | 6.7 | 150.3 | (72.0-276.5) |  | Female | 9 | 15.5 | 58.2 | (26.6-110.6) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 13 | 7.5 | 173.0 | (92.0-295.9) |  |  |  |  |  |  |
| Female | 4 | 2.7 | nc | (nc-nc) |  | Female | 21 | 19.2 | 109.2 | (67.6-167.0) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 53 | 38.4 | 138.0 | (103.3-180.5) |  | Male | 265 | 280.4 | 94.5 | (83.5-106.6) |
| Female | 53 | 42.0 | 126.1 | (94.4-164.9) |  | Female | 286 | 295.5 | 96.8 | (85.9-108.7) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

113

# Georgetown

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 4 | 8.6 | nc | (nc-nc) |  | Male | 7 | 5.7 | 123.5 | (49.5-254.5) |
| Female | 1 | 2.6 | nc | (nc-nc) |  | Female | 2 | 4.1 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 1 | 1.8 | nc | (nc-nc) |  | Male | 0 | 1.8 | nc | (nc-nc) |
| Female | 1 | 1.4 | nc | (nc-nc) |  | Female | 2 | 1.3 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  | Male | 8 | 5.1 | 156.6 | (67.4-308.6) |
| Female | 32 | 35.1 | 91.2 | (62.4-128.8) |  | Female | 1 | 4.0 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 1 | 4.4 | nc | (nc-nc) |
| Female | 1 | 1.2 | nc | (nc-nc) |  | Female | 0 | 1.7 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 7 | 9.7 | 72.3 | (29.0-149.0) |  |  |  |  |  |  |
| Female | 7 | 8.0 | 87.5 | (35.1-180.4) |  | Female | 0 | 2.9 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 3 | 2.3 | nc | (nc-nc) |  | Male | 4 | 3.1 | nc | (nc-nc) |
| Female | 1 | 0.5 | nc | (nc-nc) |  | Female | 3 | 2.7 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.6 | nc | (nc-nc) |  | Male | 35 | 29.3 | 119.5 | (83.2-166.2) |
| Female | 0 | 0.5 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 5 | 5.2 | 95.6 | (30.8-223.1) |  | Male | 2 | 2.1 | nc | (nc-nc) |
| Female | 3 | 2.6 | nc | (nc-nc) |  | Female | 0 | 1.0 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 1 | 1.4 | nc | (nc-nc) |  | Male | 2 | 1.1 | nc | (nc-nc) |
| Female | 0 | 0.4 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 1 | 3.6 | nc | (nc-nc) |  | Male | 3 | 2.4 | nc | (nc-nc) |
| Female | 2 | 2.2 | nc | (nc-nc) |  | Female | 4 | 6.7 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 3 | 3.1 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 1 | 0.9 | nc | (nc-nc) |  | Female | 11 | 7.9 | 139.3 | (69.4-249.2) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 8 | 15.8 | 50.7 | (21.8-100.0) |  | Male | 105 | 116.4 | 90.2 | (73.8-109.2) |
| Female | 12 | 14.7 | 81.6 | (42.1-142.6) |  | Female | 96 | 110.7 | 86.8 | (70.3-105.9) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

114

# Gill

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 3 | 1.9 | nc | (nc-nc) |  | Male | 0 | 1.2 | nc | (nc-nc) |
| Female | 1 | 0.6 | nc | (nc-nc) |  | Female | 1 | 0.9 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 1 | 0.4 | nc | (nc-nc) |  | Male | 0 | 0.4 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  | Female | 0 | 0.3 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 0 | 1.1 | nc | (nc-nc) |
| Female | 6 | 7.7 | 77.6 | (28.3-168.8) |  | Female | 0 | 0.9 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 1 | 1.0 | nc | (nc-nc) |
| Female | 1 | 0.3 | nc | (nc-nc) |  | Female | 2 | 0.4 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 1 | 2.1 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 1 | 1.8 | nc | (nc-nc) |  | Female | 1 | 0.7 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 0 | 0.5 | nc | (nc-nc) |  | Male | 0 | 0.7 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 1 | 0.6 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 1 | 0.1 | nc | (nc-nc) |  | Male | 3 | 6.9 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 0 | 1.1 | nc | (nc-nc) |  | Male | 0 | 0.5 | nc | (nc-nc) |
| Female | 1 | 0.6 | nc | (nc-nc) |  | Female | 0 | 0.2 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  | Male | 0 | 0.2 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 0 | 0.7 | nc | (nc-nc) |  | Male | 0 | 0.5 | nc | (nc-nc) |
| Female | 0 | 0.5 | nc | (nc-nc) |  | Female | 0 | 1.4 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 1 | 0.8 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 1 | 1.8 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 9 | 3.4 | 261.2 | (119.2-495.9) |  | Male | 22 | 26.0 | 84.8 | (53.1-128.3) |
| Female | 4 | 3.3 | nc | (nc-nc) |  | Female | 22 | 24.7 | 88.9 | (55.7-134.7) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

115

# Gloucester

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 41 | 38.3 | 107.1 | (76.9-145.3) |  | Male | 27 | 23.7 | 113.8 | (75.0-165.6) |
| Female | 23 | 14.8 | 155.6 | (98.6-233.4) |  | Female | 19 | 19.1 | 99.6 | (60.0-155.6) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 3 | 6.8 | nc | (nc-nc) |  | Male | 7 | 7.8 | 89.3 | (35.8-183.9) |
| Female | 5 | 6.0 | 83.5 | (26.9-194.8) |  | Female | 3 | 6.7 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 2 | 1.3 | nc | (nc-nc) |  | Male | 25 | 21.3 | 117.2 | (75.8-173.0) |
| Female | 171 | 158.7 | 107.7 | (92.2-125.1) |  | Female | 24 | 20.3 | 118.4 | (75.8-176.2) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 22 | 18.2 | 120.9 | (75.8-183.1) |
| Female | 3 | 4.8 | nc | (nc-nc) |  | Female | 10 | 8.5 | 117.4 | (56.2-215.9) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 41 | 40.3 | 101.7 | (73.0-138.0) |  |  |  |  |  |  |
| Female | 49 | 42.1 | 116.3 | (86.0-153.7) |  | Female | 20 | 13.7 | 146.1 | (89.2-225.7) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 14 | 10.1 | 138.6 | (75.7-232.5) |  | Male | 24 | 13.8 | 174.4 | (111.7-259.5) |
| Female | 1 | 2.9 | nc | (nc-nc) |  | Female | 11 | 15.0 | 73.5 | (36.7-131.6) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 3 | 2.4 | nc | (nc-nc) |  | Male | 134 | 128.3 | 104.5 | (87.5-123.7) |
| Female | 4 | 2.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 22 | 21.1 | 104.2 | (65.3-157.8) |  | Male | 9 | 9.2 | 98.3 | (44.9-186.7) |
| Female | 13 | 12.7 | 102.3 | (54.4-174.9) |  | Female | 2 | 5.7 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 8 | 5.9 | 136.1 | (58.6-268.2) |  | Male | 4 | 3.9 | nc | (nc-nc) |
| Female | 3 | 1.8 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 24 | 14.9 | 160.6 | (102.9-239.0) |  | Male | 12 | 8.8 | 136.8 | (70.6-239.0) |
| Female | 12 | 11.3 | 105.8 | (54.6-184.8) |  | Female | 26 | 26.1 | 99.5 | (65.0-145.8) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 6 | 13.6 | 44.2 | (16.1-96.2) |  |  |  |  |  |  |
| Female | 6 | 4.8 | 123.8 | (45.2-269.4) |  | Female | 27 | 36.3 | 74.4 | (49.0-108.2) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 88 | 68.7 | 128.1 | (102.7-157.8) |  | Male | 561 | 497.0 | 112.9 | (103.7-122.6) |
| Female | 101 | 78.0 | 129.5 | (105.5-157.4) |  | Female | 575 | 534.9 | 107.5 | (98.9-116.6) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

116

# Goshen

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 2 | 1.2 | nc | (nc-nc) |  | Male | 0 | 0.8 | nc | (nc-nc) |
| Female | 0 | 0.4 | nc | (nc-nc) |  | Female | 0 | 0.7 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 0 | 0.3 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 0 | 0.2 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.0 | nc | (nc-nc) |  | Male | 3 | 0.7 | nc | (nc-nc) |
| Female | 4 | 5.8 | nc | (nc-nc) |  | Female | 0 | 0.7 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 1 | 0.7 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 0 | 0.3 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 1 | 1.4 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 1 | 1.4 | nc | (nc-nc) |  | Female | 0 | 0.5 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  | Male | 0 | 0.5 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 0 | 0.5 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 3 | 4.5 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 0 | 0.8 | nc | (nc-nc) |  | Male | 0 | 0.3 | nc | (nc-nc) |
| Female | 1 | 0.4 | nc | (nc-nc) |  | Female | 0 | 0.2 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 1 | 0.2 | nc | (nc-nc) |  | Male | 0 | 0.1 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 0 | 0.5 | nc | (nc-nc) |  | Male | 0 | 0.4 | nc | (nc-nc) |
| Female | 0 | 0.4 | nc | (nc-nc) |  | Female | 1 | 1.1 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 1 | 0.5 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 2 | 1.3 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 1 | 2.3 | nc | (nc-nc) |  | Male | 13 | 16.9 | 77.0 | (41.0-131.7) |
| Female | 0 | 2.4 | nc | (nc-nc) |  | Female | 11 | 18.5 | 59.5 | (29.7-106.5) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

117

# Gosnold

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 0 | 0.1 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 0 | 0.1 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 0.0 | nc | (nc-nc) |  | Male | 0 | 0.0 | nc | (nc-nc) |
| Female | 0 | 0.0 | nc | (nc-nc) |  | Female | 0 | 0.0 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.0 | nc | (nc-nc) |  | Male | 0 | 0.1 | nc | (nc-nc) |
| Female | 0 | 0.9 | nc | (nc-nc) |  | Female | 0 | 0.1 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 0 | 0.1 | nc | (nc-nc) |
| Female | 0 | 0.0 | nc | (nc-nc) |  | Female | 0 | 0.0 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 0 | 0.1 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 0 | 0.0 | nc | (nc-nc) |  | Male | 0 | 0.1 | nc | (nc-nc) |
| Female | 0 | 0.0 | nc | (nc-nc) |  | Female | 0 | 0.1 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.0 | nc | (nc-nc) |  | Male | 0 | 0.5 | nc | (nc-nc) |
| Female | 0 | 0.0 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 0 | 0.0 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 0 | 0.0 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 0.0 | nc | (nc-nc) |  | Male | 0 | 0.0 | nc | (nc-nc) |
| Female | 0 | 0.0 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 0 | 0.0 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 0 | 0.1 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.0 | nc | (nc-nc) |  | Female | 0 | 0.2 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  | Male | 0 | 1.9 | nc | (nc-nc) |
| Female | 0 | 0.4 | nc | (nc-nc) |  | Female | 0 | 2.8 | nc | (nc-nc) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

118

# Grafton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 19 | 16.5 | 115.4 | (69.5-180.3) |  | Male | 9 | 11.1 | 81.3 | (37.1-154.4) |
| Female | 5 | 5.7 | 88.3 | (28.5-206.2) |  | Female | 9 | 8.7 | 103.6 | (47.3-196.6) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 9 | 3.6 | 251.1 | (114.6-476.7) |  | Male | 4 | 3.4 | nc | (nc-nc) |
| Female | 3 | 2.8 | nc | (nc-nc) |  | Female | 2 | 2.6 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.6 | nc | (nc-nc) |  | Male | 6 | 9.9 | 60.4 | (22.1-131.5) |
| Female | 78 | 70.4 | 110.8 | (87.5-138.2) |  | Female | 7 | 8.3 | 84.6 | (33.9-174.3) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 14 | 8.4 | 165.8 | (90.6-278.3) |
| Female | 3 | 2.6 | nc | (nc-nc) |  | Female | 3 | 3.5 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 14 | 18.8 | 74.3 | (40.6-124.7) |  |  |  |  |  |  |
| Female | 19 | 17.0 | 111.9 | (67.3-174.7) |  | Female | 4 | 5.9 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 3 | 4.3 | nc | (nc-nc) |  | Male | 3 | 6.0 | nc | (nc-nc) |
| Female | 0 | 1.1 | nc | (nc-nc) |  | Female | 4 | 5.7 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 1.4 | nc | (nc-nc) |  | Male | 59 | 52.0 | 113.5 | (86.4-146.5) |
| Female | 1 | 1.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 14 | 9.8 | 142.5 | (77.8-239.1) |  | Male | 2 | 4.1 | nc | (nc-nc) |
| Female | 5 | 5.4 | 91.9 | (29.6-214.5) |  | Female | 2 | 2.3 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 7 | 2.5 | 279.8 | (112.1-576.5) |  | Male | 3 | 2.7 | nc | (nc-nc) |
| Female | 2 | 0.8 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 11 | 7.2 | 153.8 | (76.7-275.1) |  | Male | 7 | 4.8 | 145.5 | (58.3-299.8) |
| Female | 9 | 4.9 | 185.0 | (84.4-351.2) |  | Female | 15 | 14.3 | 104.6 | (58.5-172.5) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 4 | 6.0 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 1.9 | nc | (nc-nc) |  | Female | 15 | 15.3 | 98.2 | (54.9-162.0) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 32 | 29.1 | 109.9 | (75.1-155.1) |  | Male | 232 | 220.3 | 105.3 | (92.2-119.8) |
| Female | 36 | 30.8 | 117.0 | (81.9-162.0) |  | Female | 243 | 228.7 | 106.3 | (93.3-120.5) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

119

# Granby

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 4 | 6.1 | nc | (nc-nc) |  | Male | 2 | 4.2 | nc | (nc-nc) |
| Female | 3 | 2.5 | nc | (nc-nc) |  | Female | 3 | 3.7 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 2 | 1.3 | nc | (nc-nc) |  | Male | 0 | 1.3 | nc | (nc-nc) |
| Female | 2 | 1.2 | nc | (nc-nc) |  | Female | 0 | 1.2 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 7 | 3.7 | 189.9 | (76.1-391.4) |
| Female | 18 | 30.3 | 59.4 | (35.2-93.9) |  | Female | 2 | 3.7 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 2 | 3.4 | nc | (nc-nc) |
| Female | 1 | 1.0 | nc | (nc-nc) |  | Female | 1 | 1.6 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 8 | 6.9 | 115.2 | (49.6-227.0) |  |  |  |  |  |  |
| Female | 7 | 7.6 | 92.1 | (36.9-189.9) |  | Female | 4 | 2.6 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 4 | 1.7 | nc | (nc-nc) |  | Male | 1 | 2.3 | nc | (nc-nc) |
| Female | 0 | 0.5 | nc | (nc-nc) |  | Female | 1 | 2.7 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 2 | 0.5 | nc | (nc-nc) |  | Male | 18 | 22.2 | 80.9 | (47.9-127.9) |
| Female | 0 | 0.4 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 4 | 3.8 | nc | (nc-nc) |  | Male | 2 | 1.5 | nc | (nc-nc) |
| Female | 8 | 2.3 | 347.8 | (149.8-685.4) |  | Female | 0 | 1.1 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 1 | 1.0 | nc | (nc-nc) |  | Male | 1 | 0.8 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 2 | 2.6 | nc | (nc-nc) |  | Male | 0 | 1.8 | nc | (nc-nc) |
| Female | 1 | 2.1 | nc | (nc-nc) |  | Female | 1 | 5.7 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 1 | 2.5 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 2 | 0.9 | nc | (nc-nc) |  | Female | 6 | 6.9 | 87.4 | (31.9-190.3) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 15 | 11.2 | 134.2 | (75.1-221.4) |  | Male | 83 | 85.7 | 96.8 | (77.1-120.0) |
| Female | 11 | 13.1 | 84.2 | (42.0-150.6) |  | Female | 77 | 99.1 | 77.7 | (61.3-97.1) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

120

# Granville

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 4 | 2.2 | nc | (nc-nc) |  | Male | 1 | 1.4 | nc | (nc-nc) |
| Female | 1 | 0.6 | nc | (nc-nc) |  | Female | 1 | 0.9 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 0.4 | nc | (nc-nc) |  | Male | 1 | 0.5 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  | Female | 0 | 0.3 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 4 | 1.2 | nc | (nc-nc) |
| Female | 7 | 7.5 | 93.0 | (37.2-191.6) |  | Female | 0 | 0.9 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 1 | 1.1 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 0 | 0.4 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 1 | 2.3 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 2 | 1.8 | nc | (nc-nc) |  | Female | 1 | 0.6 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 0 | 0.6 | nc | (nc-nc) |  | Male | 0 | 0.8 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 0 | 0.6 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 10 | 7.6 | 131.9 | (63.1-242.5) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 3 | 1.2 | nc | (nc-nc) |  | Male | 0 | 0.5 | nc | (nc-nc) |
| Female | 0 | 0.6 | nc | (nc-nc) |  | Female | 0 | 0.2 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  | Male | 0 | 0.2 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 1 | 0.8 | nc | (nc-nc) |  | Male | 0 | 0.5 | nc | (nc-nc) |
| Female | 0 | 0.5 | nc | (nc-nc) |  | Female | 3 | 1.3 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 0 | 0.8 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 5 | 1.8 | 285.2 | (91.9-665.5) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 2 | 4.0 | nc | (nc-nc) |  | Male | 28 | 28.8 | 97.4 | (64.7-140.7) |
| Female | 4 | 3.5 | nc | (nc-nc) |  | Female | 25 | 24.2 | 103.3 | (66.8-152.5) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

121

# Great Barrington

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 13 | 7.8 | 167.4 | (89.1-286.3) |  | Male | 8 | 4.9 | 162.1 | (69.8-319.4) |
| Female | 6 | 3.8 | 159.8 | (58.3-347.8) |  | Female | 3 | 4.4 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 1 | 1.5 | nc | (nc-nc) |  | Male | 2 | 1.6 | nc | (nc-nc) |
| Female | 2 | 1.4 | nc | (nc-nc) |  | Female | 2 | 1.6 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 1 | 0.3 | nc | (nc-nc) |  | Male | 3 | 4.5 | nc | (nc-nc) |
| Female | 38 | 35.4 | 107.5 | (76.1-147.5) |  | Female | 4 | 4.9 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 3 | 3.6 | nc | (nc-nc) |
| Female | 2 | 1.0 | nc | (nc-nc) |  | Female | 2 | 2.0 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 6 | 8.4 | 71.3 | (26.0-155.3) |  |  |  |  |  |  |
| Female | 11 | 10.5 | 104.3 | (52.0-186.7) |  | Female | 2 | 3.1 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 0 | 2.0 | nc | (nc-nc) |  | Male | 3 | 2.7 | nc | (nc-nc) |
| Female | 0 | 0.7 | nc | (nc-nc) |  | Female | 2 | 3.9 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.6 | nc | (nc-nc) |  | Male | 31 | 23.1 | 134.4 | (91.3-190.7) |
| Female | 0 | 0.5 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 4 | 4.2 | nc | (nc-nc) |  | Male | 3 | 1.9 | nc | (nc-nc) |
| Female | 1 | 2.9 | nc | (nc-nc) |  | Female | 0 | 1.4 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 3 | 1.1 | nc | (nc-nc) |  | Male | 1 | 1.1 | nc | (nc-nc) |
| Female | 0 | 0.4 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 3 | 3.2 | nc | (nc-nc) |  | Male | 1 | 2.0 | nc | (nc-nc) |
| Female | 3 | 2.8 | nc | (nc-nc) |  | Female | 8 | 5.4 | 147.2 | (63.4-290.1) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 3 | 2.7 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 1 | 1.2 | nc | (nc-nc) |  | Female | 5 | 8.1 | 61.9 | (20.0-144.5) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 17 | 13.4 | 126.8 | (73.8-203.0) |  | Male | 116 | 98.7 | 117.5 | (97.1-140.9) |
| Female | 23 | 19.0 | 121.1 | (76.8-181.8) |  | Female | 126 | 125.5 | 100.4 | (83.7-119.6) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

122

# Greenfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 18 | 21.5 | 83.6 | (49.5-132.2) |  | Male | 9 | 13.5 | 66.4 | (30.3-126.1) |
| Female | 6 | 7.7 | 77.9 | (28.4-169.5) |  | Female | 7 | 10.2 | 68.7 | (27.5-141.5) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 6 | 4.0 | 150.0 | (54.8-326.5) |  | Male | 4 | 4.4 | nc | (nc-nc) |
| Female | 6 | 3.2 | 187.5 | (68.5-408.1) |  | Female | 3 | 3.5 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.7 | nc | (nc-nc) |  | Male | 4 | 12.1 | nc | (nc-nc) |
| Female | 71 | 80.7 | 88.0 | (68.7-111.0) |  | Female | 12 | 10.6 | 113.1 | (58.4-197.6) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 9 | 10.0 | 89.6 | (40.9-170.1) |
| Female | 3 | 2.7 | nc | (nc-nc) |  | Female | 3 | 4.4 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 26 | 22.8 | 114.1 | (74.5-167.2) |  |  |  |  |  |  |
| Female | 27 | 22.6 | 119.3 | (78.6-173.6) |  | Female | 6 | 7.0 | 85.4 | (31.2-185.8) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 3 | 5.5 | nc | (nc-nc) |  | Male | 9 | 7.7 | 116.5 | (53.2-221.1) |
| Female | 3 | 1.5 | nc | (nc-nc) |  | Female | 8 | 8.0 | 100.4 | (43.2-197.8) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 5 | 1.5 | 326.3 | (105.2-761.5) |  | Male | 36 | 68.4 | 52.7 | (36.9-72.9) |
| Female | 2 | 1.2 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 7 | 11.7 | 59.6 | (23.9-122.8) |  | Male | 3 | 5.2 | nc | (nc-nc) |
| Female | 5 | 6.5 | 77.2 | (24.9-180.1) |  | Female | 4 | 3.1 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 1 | 3.3 | nc | (nc-nc) |  | Male | 1 | 2.7 | nc | (nc-nc) |
| Female | 0 | 0.9 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 6 | 8.6 | 70.1 | (25.6-152.6) |  | Male | 3 | 5.2 | nc | (nc-nc) |
| Female | 6 | 6.2 | 97.3 | (35.5-211.7) |  | Female | 4 | 14.3 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 4 | 7.6 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 5 | 2.5 | 200.2 | (64.5-467.1) |  | Female | 20 | 18.2 | 109.9 | (67.1-169.7) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 27 | 38.3 | 70.6 | (46.5-102.7) |  | Male | 205 | 276.9 | 74.0 | (64.2-84.9) |
| Female | 48 | 38.8 | 123.7 | (91.2-164.0) |  | Female | 275 | 277.2 | 99.2 | (87.8-111.7) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

123

# Groton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 7 | 11.1 | 62.8 | (25.2-129.4) |  | Male | 3 | 7.5 | nc | (nc-nc) |
| Female | 0 | 3.6 | nc | (nc-nc) |  | Female | 4 | 5.6 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 2 | 2.3 | nc | (nc-nc) |  | Male | 2 | 2.4 | nc | (nc-nc) |
| Female | 1 | 1.8 | nc | (nc-nc) |  | Female | 1 | 1.7 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 1 | 0.4 | nc | (nc-nc) |  | Male | 3 | 6.8 | nc | (nc-nc) |
| Female | 38 | 48.0 | 79.1 | (56.0-108.6) |  | Female | 5 | 5.4 | 92.3 | (29.7-215.4) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 6 | 6.0 | 99.6 | (36.4-216.8) |
| Female | 2 | 1.6 | nc | (nc-nc) |  | Female | 1 | 2.4 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 16 | 12.8 | 124.7 | (71.2-202.5) |  |  |  |  |  |  |
| Female | 10 | 11.1 | 90.4 | (43.3-166.2) |  | Female | 2 | 4.0 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 1 | 3.1 | nc | (nc-nc) |  | Male | 4 | 4.2 | nc | (nc-nc) |
| Female | 0 | 0.7 | nc | (nc-nc) |  | Female | 3 | 3.6 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.9 | nc | (nc-nc) |  | Male | 31 | 38.6 | 80.2 | (54.5-113.9) |
| Female | 0 | 0.6 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 4 | 6.9 | nc | (nc-nc) |  | Male | 2 | 2.8 | nc | (nc-nc) |
| Female | 2 | 3.6 | nc | (nc-nc) |  | Female | 2 | 1.5 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 1 | 1.8 | nc | (nc-nc) |  | Male | 5 | 1.4 | 358.0 | (115.4-835.4) |
| Female | 0 | 0.5 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 3 | 4.7 | nc | (nc-nc) |  | Male | 6 | 3.2 | 190.2 | (69.5-414.0) |
| Female | 0 | 3.0 | nc | (nc-nc) |  | Female | 8 | 9.1 | 88.0 | (37.9-173.5) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 2 | 4.4 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 2 | 1.3 | nc | (nc-nc) |  | Female | 12 | 10.8 | 110.8 | (57.2-193.5) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 11 | 20.3 | 54.1 | (27.0-96.9) |  | Male | 122 | 153.5 | 79.5 | (66.0-94.9) |
| Female | 10 | 19.8 | 50.5 | (24.2-92.9) |  | Female | 110 | 151.1 | 72.8 | (59.8-87.7) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

124

# Groveland

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 6 | 8.5 | 70.8 | (25.8-154.0) |  | Male | 5 | 5.4 | 93.4 | (30.1-218.0) |
| Female | 3 | 2.8 | nc | (nc-nc) |  | Female | 11 | 3.9 | 285.4 | (142.3-510.7) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 1 | 1.6 | nc | (nc-nc) |  | Male | 0 | 1.8 | nc | (nc-nc) |
| Female | 1 | 1.2 | nc | (nc-nc) |  | Female | 1 | 1.3 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  | Male | 7 | 4.8 | 145.6 | (58.3-300.0) |
| Female | 39 | 33.0 | 118.2 | (84.0-161.5) |  | Female | 6 | 3.9 | 152.1 | (55.5-331.1) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 2 | 4.0 | nc | (nc-nc) |
| Female | 2 | 1.0 | nc | (nc-nc) |  | Female | 2 | 1.7 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 3 | 9.1 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 6 | 8.0 | 74.9 | (27.4-163.1) |  | Female | 4 | 2.8 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 2 | 2.2 | nc | (nc-nc) |  | Male | 5 | 3.0 | 165.0 | (53.2-385.1) |
| Female | 1 | 0.6 | nc | (nc-nc) |  | Female | 3 | 2.8 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.6 | nc | (nc-nc) |  | Male | 29 | 26.6 | 108.8 | (72.9-156.3) |
| Female | 0 | 0.4 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 2 | 4.7 | nc | (nc-nc) |  | Male | 2 | 2.0 | nc | (nc-nc) |
| Female | 3 | 2.6 | nc | (nc-nc) |  | Female | 3 | 1.1 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 2 | 1.3 | nc | (nc-nc) |  | Male | 0 | 1.0 | nc | (nc-nc) |
| Female | 1 | 0.4 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 2 | 3.4 | nc | (nc-nc) |  | Male | 2 | 2.0 | nc | (nc-nc) |
| Female | 2 | 2.2 | nc | (nc-nc) |  | Female | 8 | 5.5 | 145.2 | (62.5-286.1) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 0 | 2.9 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 1 | 1.0 | nc | (nc-nc) |  | Female | 5 | 7.7 | 65.3 | (21.0-152.4) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 10 | 15.3 | 65.3 | (31.2-120.0) |  | Male | 86 | 109.3 | 78.7 | (62.9-97.2) |
| Female | 14 | 15.1 | 92.8 | (50.7-155.7) |  | Female | 121 | 107.2 | 112.8 | (93.6-134.8) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

125

# Hadley

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 6 | 7.0 | 86.2 | (31.5-187.6) |  | Male | 2 | 4.2 | nc | (nc-nc) |
| Female | 2 | 3.2 | nc | (nc-nc) |  | Female | 3 | 3.7 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 1.2 | nc | (nc-nc) |  | Male | 1 | 1.4 | nc | (nc-nc) |
| Female | 0 | 1.2 | nc | (nc-nc) |  | Female | 0 | 1.4 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 2 | 3.8 | nc | (nc-nc) |
| Female | 27 | 30.1 | 89.7 | (59.1-130.5) |  | Female | 5 | 4.2 | 120.3 | (38.8-280.7) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 6 | 3.1 | 196.7 | (71.8-428.1) |
| Female | 1 | 0.9 | nc | (nc-nc) |  | Female | 0 | 1.7 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 5 | 7.1 | 70.4 | (22.7-164.4) |  |  |  |  |  |  |
| Female | 12 | 8.8 | 137.1 | (70.7-239.4) |  | Female | 2 | 2.6 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 1 | 1.8 | nc | (nc-nc) |  | Male | 3 | 2.4 | nc | (nc-nc) |
| Female | 0 | 0.6 | nc | (nc-nc) |  | Female | 1 | 3.3 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.5 | nc | (nc-nc) |  | Male | 19 | 21.6 | 88.1 | (53.0-137.6) |
| Female | 0 | 0.4 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 2 | 3.6 | nc | (nc-nc) |  | Male | 2 | 1.6 | nc | (nc-nc) |
| Female | 3 | 2.5 | nc | (nc-nc) |  | Female | 0 | 1.2 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 1.0 | nc | (nc-nc) |  | Male | 0 | 0.8 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 1 | 2.7 | nc | (nc-nc) |  | Male | 1 | 1.5 | nc | (nc-nc) |
| Female | 4 | 2.4 | nc | (nc-nc) |  | Female | 4 | 4.6 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 0 | 2.3 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 1 | 1.0 | nc | (nc-nc) |  | Female | 13 | 6.9 | 188.8 | (100.4-322.8) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 5 | 12.3 | 40.6 | (13.1-94.7) |  | Male | 66 | 86.7 | 76.1 | (58.8-96.8) |
| Female | 7 | 16.1 | 43.4 | (17.4-89.3) |  | Female | 88 | 106.3 | 82.8 | (66.4-102.0) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

126

# Halifax

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 7 | 7.7 | 90.8 | (36.4-187.1) |  | Male | 4 | 5.2 | nc | (nc-nc) |
| Female | 1 | 3.0 | nc | (nc-nc) |  | Female | 3 | 4.2 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 2 | 1.6 | nc | (nc-nc) |  | Male | 2 | 1.7 | nc | (nc-nc) |
| Female | 2 | 1.3 | nc | (nc-nc) |  | Female | 1 | 1.4 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  | Male | 4 | 4.7 | nc | (nc-nc) |
| Female | 32 | 34.9 | 91.8 | (62.8-129.5) |  | Female | 6 | 4.3 | 139.9 | (51.1-304.5) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 5 | 4.0 | 126.2 | (40.7-294.5) |
| Female | 1 | 1.2 | nc | (nc-nc) |  | Female | 1 | 1.8 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 13 | 8.9 | 146.6 | (78.0-250.7) |  |  |  |  |  |  |
| Female | 13 | 9.0 | 143.8 | (76.5-245.9) |  | Female | 3 | 2.9 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 4 | 2.0 | nc | (nc-nc) |  | Male | 8 | 2.8 | 283.7 | (122.1-559.0) |
| Female | 1 | 0.6 | nc | (nc-nc) |  | Female | 2 | 3.0 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.7 | nc | (nc-nc) |  | Male | 36 | 23.9 | 150.5 | (105.4-208.3) |
| Female | 0 | 0.5 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 8 | 4.6 | 172.8 | (74.4-340.6) |  | Male | 1 | 1.9 | nc | (nc-nc) |
| Female | 5 | 2.7 | 183.3 | (59.1-427.7) |  | Female | 1 | 1.2 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 1 | 1.2 | nc | (nc-nc) |  | Male | 2 | 1.2 | nc | (nc-nc) |
| Female | 1 | 0.4 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 4 | 3.2 | nc | (nc-nc) |  | Male | 3 | 2.2 | nc | (nc-nc) |
| Female | 2 | 2.4 | nc | (nc-nc) |  | Female | 12 | 6.3 | 190.8 | (98.5-333.3) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 3 | 2.8 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 2 | 1.0 | nc | (nc-nc) |  | Female | 13 | 7.4 | 175.5 | (93.4-300.1) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 17 | 13.9 | 122.2 | (71.2-195.7) |  | Male | 131 | 102.7 | 127.5 | (106.6-151.3) |
| Female | 16 | 16.2 | 98.5 | (56.3-159.9) |  | Female | 128 | 114.9 | 111.4 | (92.9-132.5) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

127

# Hamilton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 6 | 8.0 | 75.1 | (27.4-163.4) |  | Male | 4 | 5.2 | nc | (nc-nc) |
| Female | 4 | 2.9 | nc | (nc-nc) |  | Female | 6 | 4.2 | 143.8 | (52.5-313.0) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 1.7 | nc | (nc-nc) |  | Male | 4 | 1.7 | nc | (nc-nc) |
| Female | 3 | 1.3 | nc | (nc-nc) |  | Female | 0 | 1.4 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  | Male | 4 | 4.7 | nc | (nc-nc) |
| Female | 41 | 34.5 | 118.8 | (85.2-161.1) |  | Female | 11 | 4.2 | 263.3 | (131.3-471.2) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 4 | 4.0 | nc | (nc-nc) |
| Female | 0 | 1.1 | nc | (nc-nc) |  | Female | 1 | 1.8 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 3 | 8.8 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 11 | 8.6 | 127.4 | (63.5-228.0) |  | Female | 1 | 3.0 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 3 | 2.1 | nc | (nc-nc) |  | Male | 0 | 2.9 | nc | (nc-nc) |
| Female | 0 | 0.6 | nc | (nc-nc) |  | Female | 1 | 2.9 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 1 | 0.7 | nc | (nc-nc) |  | Male | 26 | 26.4 | 98.4 | (64.3-144.2) |
| Female | 0 | 0.5 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 8 | 4.7 | 171.5 | (73.8-337.9) |  | Male | 1 | 1.9 | nc | (nc-nc) |
| Female | 3 | 2.7 | nc | (nc-nc) |  | Female | 0 | 1.2 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 1.2 | nc | (nc-nc) |  | Male | 1 | 1.2 | nc | (nc-nc) |
| Female | 1 | 0.4 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 5 | 3.4 | 148.5 | (47.9-346.7) |  | Male | 5 | 2.1 | 232.7 | (75.0-543.0) |
| Female | 3 | 2.4 | nc | (nc-nc) |  | Female | 7 | 6.3 | 111.1 | (44.5-228.9) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 1 | 2.9 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 1.0 | nc | (nc-nc) |  | Female | 5 | 7.7 | 64.6 | (20.8-150.7) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 14 | 14.5 | 96.8 | (52.9-162.4) |  | Male | 100 | 106.6 | 93.8 | (76.3-114.1) |
| Female | 12 | 15.7 | 76.3 | (39.4-133.3) |  | Female | 122 | 113.1 | 107.9 | (89.6-128.8) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

128

# Hampden

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 8 | 8.4 | 95.6 | (41.2-188.4) |  | Male | 2 | 5.1 | nc | (nc-nc) |
| Female | 0 | 2.5 | nc | (nc-nc) |  | Female | 2 | 3.2 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 1 | 1.4 | nc | (nc-nc) |  | Male | 1 | 1.7 | nc | (nc-nc) |
| Female | 1 | 1.0 | nc | (nc-nc) |  | Female | 1 | 1.1 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  | Male | 8 | 4.5 | 177.1 | (76.2-348.9) |
| Female | 23 | 26.6 | 86.4 | (54.7-129.6) |  | Female | 2 | 3.4 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 2 | 3.7 | nc | (nc-nc) |
| Female | 2 | 0.8 | nc | (nc-nc) |  | Female | 1 | 1.4 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 4 | 8.5 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 3 | 7.2 | nc | (nc-nc) |  | Female | 1 | 2.3 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 1 | 2.1 | nc | (nc-nc) |  | Male | 3 | 2.9 | nc | (nc-nc) |
| Female | 0 | 0.5 | nc | (nc-nc) |  | Female | 3 | 2.6 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.4 | nc | (nc-nc) |  | Male | 20 | 25.7 | 77.7 | (47.4-120.0) |
| Female | 0 | 0.3 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 5 | 4.4 | 114.1 | (36.8-266.2) |  | Male | 1 | 2.0 | nc | (nc-nc) |
| Female | 0 | 2.1 | nc | (nc-nc) |  | Female | 1 | 1.0 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 1.3 | nc | (nc-nc) |  | Male | 5 | 0.6 | 801.5 | (258.3-1870.3) |
| Female | 0 | 0.3 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 3 | 3.2 | nc | (nc-nc) |  | Male | 2 | 1.8 | nc | (nc-nc) |
| Female | 1 | 1.9 | nc | (nc-nc) |  | Female | 4 | 4.3 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 3 | 2.8 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.8 | nc | (nc-nc) |  | Female | 5 | 6.0 | 82.7 | (26.7-193.1) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 9 | 15.2 | 59.2 | (27.0-112.3) |  | Male | 81 | 104.3 | 77.7 | (61.7-96.6) |
| Female | 8 | 13.0 | 61.6 | (26.5-121.4) |  | Female | 63 | 89.8 | 70.2 | (53.9-89.8) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

129

# Hancock

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 2 | 0.8 | nc | (nc-nc) |  | Male | 0 | 0.5 | nc | (nc-nc) |
| Female | 1 | 0.3 | nc | (nc-nc) |  | Female | 1 | 0.4 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 0 | 0.2 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 0 | 0.1 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.0 | nc | (nc-nc) |  | Male | 1 | 0.5 | nc | (nc-nc) |
| Female | 2 | 3.4 | nc | (nc-nc) |  | Female | 0 | 0.4 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 1 | 0.4 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 0 | 0.2 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 0 | 0.8 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.8 | nc | (nc-nc) |  | Female | 0 | 0.3 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 0 | 0.3 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 0 | 0.3 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 4 | 2.9 | nc | (nc-nc) |
| Female | 0 | 0.0 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 0 | 0.5 | nc | (nc-nc) |  | Male | 0 | 0.2 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  | Female | 0 | 0.1 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 1 | 0.1 | nc | (nc-nc) |
| Female | 0 | 0.0 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  | Male | 0 | 0.2 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 0 | 0.6 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 1 | 0.3 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 1 | 0.8 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 0 | 1.4 | nc | (nc-nc) |  | Male | 11 | 10.7 | 102.7 | (51.2-183.8) |
| Female | 2 | 1.5 | nc | (nc-nc) |  | Female | 9 | 11.0 | 81.9 | (37.4-155.5) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

130

# Hanover

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 14 | 12.5 | 112.2 | (61.3-188.2) |  | Male | 20 | 8.6 | 233.9 | (142.8-361.2) |
| Female | 7 | 5.2 | 134.4 | (53.8-276.8) |  | Female | 4 | 7.4 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 5 | 2.8 | 178.9 | (57.7-417.6) |  | Male | 2 | 2.8 | nc | (nc-nc) |
| Female | 1 | 2.4 | nc | (nc-nc) |  | Female | 4 | 2.4 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.5 | nc | (nc-nc) |  | Male | 8 | 7.7 | 104.5 | (45.0-205.9) |
| Female | 80 | 61.0 | 131.2 | (104.0-163.3) |  | Female | 10 | 7.4 | 134.3 | (64.3-247.0) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 7 | 6.8 | 102.4 | (41.0-210.9) |
| Female | 0 | 2.0 | nc | (nc-nc) |  | Female | 2 | 3.2 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 18 | 14.2 | 126.5 | (74.9-200.0) |  |  |  |  |  |  |
| Female | 18 | 15.1 | 119.1 | (70.5-188.2) |  | Female | 5 | 5.2 | 96.4 | (31.1-225.0) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 5 | 3.5 | 142.6 | (45.9-332.7) |  | Male | 1 | 4.7 | nc | (nc-nc) |
| Female | 1 | 1.0 | nc | (nc-nc) |  | Female | 3 | 5.3 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 1.1 | nc | (nc-nc) |  | Male | 64 | 43.8 | 146.2 | (112.6-186.7) |
| Female | 0 | 0.9 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 4 | 7.9 | nc | (nc-nc) |  | Male | 2 | 3.1 | nc | (nc-nc) |
| Female | 5 | 4.8 | 105.1 | (33.9-245.4) |  | Female | 0 | 2.1 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 2 | 2.1 | nc | (nc-nc) |  | Male | 2 | 1.9 | nc | (nc-nc) |
| Female | 1 | 0.7 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 6 | 5.5 | 109.1 | (39.8-237.5) |  | Male | 4 | 3.8 | nc | (nc-nc) |
| Female | 2 | 4.3 | nc | (nc-nc) |  | Female | 12 | 11.2 | 106.7 | (55.1-186.4) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 1 | 4.9 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 1.8 | nc | (nc-nc) |  | Female | 18 | 13.9 | 129.6 | (76.8-204.9) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 17 | 23.0 | 73.9 | (43.0-118.4) |  | Male | 188 | 174.4 | 107.8 | (92.9-124.3) |
| Female | 30 | 27.7 | 108.4 | (73.1-154.7) |  | Female | 215 | 200.9 | 107.0 | (93.2-122.3) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

131

# Hanson

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 11 | 9.5 | 115.9 | (57.8-207.5) |  | Male | 7 | 6.6 | 105.5 | (42.3-217.5) |
| Female | 3 | 3.1 | nc | (nc-nc) |  | Female | 3 | 5.0 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 1 | 2.1 | nc | (nc-nc) |  | Male | 1 | 2.2 | nc | (nc-nc) |
| Female | 0 | 1.6 | nc | (nc-nc) |  | Female | 1 | 1.5 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.4 | nc | (nc-nc) |  | Male | 2 | 6.0 | nc | (nc-nc) |
| Female | 31 | 43.0 | 72.0 | (48.9-102.2) |  | Female | 4 | 4.7 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 9 | 5.5 | 162.9 | (74.3-309.2) |
| Female | 1 | 1.5 | nc | (nc-nc) |  | Female | 2 | 2.1 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 13 | 11.1 | 116.6 | (62.0-199.4) |  |  |  |  |  |  |
| Female | 11 | 9.2 | 119.6 | (59.6-213.9) |  | Female | 3 | 3.5 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 0 | 2.8 | nc | (nc-nc) |  | Male | 5 | 3.6 | 137.4 | (44.3-320.7) |
| Female | 1 | 0.6 | nc | (nc-nc) |  | Female | 2 | 3.1 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.8 | nc | (nc-nc) |  | Male | 31 | 36.3 | 85.5 | (58.1-121.4) |
| Female | 0 | 0.7 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 5 | 6.3 | 79.1 | (25.5-184.5) |  | Male | 1 | 2.4 | nc | (nc-nc) |
| Female | 6 | 3.2 | 187.4 | (68.4-407.8) |  | Female | 0 | 1.2 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 1.6 | nc | (nc-nc) |  | Male | 2 | 1.5 | nc | (nc-nc) |
| Female | 0 | 0.4 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 2 | 4.2 | nc | (nc-nc) |  | Male | 1 | 3.0 | nc | (nc-nc) |
| Female | 4 | 2.7 | nc | (nc-nc) |  | Female | 7 | 8.4 | 83.0 | (33.3-171.0) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 4 | 3.9 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 3 | 1.1 | nc | (nc-nc) |  | Female | 10 | 9.6 | 103.9 | (49.7-191.1) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 24 | 17.8 | 135.0 | (86.5-200.9) |  | Male | 133 | 137.8 | 96.5 | (80.8-114.4) |
| Female | 22 | 17.7 | 124.4 | (77.9-188.4) |  | Female | 121 | 133.6 | 90.6 | (75.1-108.2) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

132

# Hardwick

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 2 | 4.9 | nc | (nc-nc) |  | Male | 5 | 3.0 | 169.4 | (54.6-395.3) |
| Female | 1 | 1.1 | nc | (nc-nc) |  | Female | 1 | 1.6 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 0.8 | nc | (nc-nc) |  | Male | 0 | 1.0 | nc | (nc-nc) |
| Female | 2 | 0.5 | nc | (nc-nc) |  | Female | 1 | 0.5 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 2 | 2.7 | nc | (nc-nc) |
| Female | 11 | 13.4 | 81.8 | (40.8-146.4) |  | Female | 1 | 1.6 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 0 | 2.2 | nc | (nc-nc) |
| Female | 0 | 0.4 | nc | (nc-nc) |  | Female | 0 | 0.7 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 6 | 5.0 | 119.4 | (43.6-259.8) |  |  |  |  |  |  |
| Female | 4 | 3.1 | nc | (nc-nc) |  | Female | 0 | 1.2 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 2 | 1.3 | nc | (nc-nc) |  | Male | 2 | 1.7 | nc | (nc-nc) |
| Female | 1 | 0.2 | nc | (nc-nc) |  | Female | 0 | 1.1 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  | Male | 7 | 15.5 | 45.2 | (18.1-93.1) |
| Female | 0 | 0.2 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 3 | 2.6 | nc | (nc-nc) |  | Male | 0 | 1.2 | nc | (nc-nc) |
| Female | 0 | 1.0 | nc | (nc-nc) |  | Female | 0 | 0.4 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 0.7 | nc | (nc-nc) |  | Male | 1 | 0.4 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 0 | 1.9 | nc | (nc-nc) |  | Male | 0 | 1.0 | nc | (nc-nc) |
| Female | 1 | 0.9 | nc | (nc-nc) |  | Female | 1 | 2.4 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 3 | 1.7 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.4 | nc | (nc-nc) |  | Female | 2 | 3.3 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 7 | 8.9 | 79.0 | (31.7-162.8) |  | Male | 45 | 61.6 | 73.1 | (53.3-97.8) |
| Female | 8 | 5.9 | 136.5 | (58.8-268.9) |  | Female | 35 | 43.1 | 81.2 | (56.5-112.9) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

133

# Harvard

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 5 | 8.2 | 60.6 | (19.5-141.5) |  | Male | 1 | 5.7 | nc | (nc-nc) |
| Female | 0 | 1.7 | nc | (nc-nc) |  | Female | 3 | 2.7 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 1 | 1.7 | nc | (nc-nc) |  | Male | 1 | 1.9 | nc | (nc-nc) |
| Female | 2 | 0.9 | nc | (nc-nc) |  | Female | 2 | 0.8 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 1 | 0.3 | nc | (nc-nc) |  | Male | 6 | 5.1 | 117.5 | (42.9-255.8) |
| Female | 21 | 23.6 | 88.9 | (55.0-135.9) |  | Female | 3 | 2.6 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 5 | 4.7 | 105.4 | (34.0-245.9) |
| Female | 0 | 0.8 | nc | (nc-nc) |  | Female | 0 | 1.2 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 5 | 9.8 | 51.2 | (16.5-119.6) |  |  |  |  |  |  |
| Female | 9 | 5.3 | 168.8 | (77.0-320.5) |  | Female | 3 | 2.0 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 3 | 2.4 | nc | (nc-nc) |  | Male | 0 | 3.1 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  | Female | 1 | 1.7 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.7 | nc | (nc-nc) |  | Male | 22 | 30.9 | 71.2 | (44.6-107.7) |
| Female | 0 | 0.3 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 2 | 5.4 | nc | (nc-nc) |  | Male | 1 | 2.1 | nc | (nc-nc) |
| Female | 1 | 1.8 | nc | (nc-nc) |  | Female | 0 | 0.7 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 1 | 1.4 | nc | (nc-nc) |  | Male | 0 | 1.2 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 4 | 3.4 | nc | (nc-nc) |  | Male | 0 | 2.5 | nc | (nc-nc) |
| Female | 1 | 1.5 | nc | (nc-nc) |  | Female | 5 | 4.4 | 113.7 | (36.7-265.4) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 0 | 3.4 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.6 | nc | (nc-nc) |  | Female | 6 | 5.3 | 114.1 | (41.7-248.4) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 5 | 15.5 | 32.3 | (10.4-75.4) |  | Male | 77 | 118.1 | 65.2 | (51.4-81.5) |
| Female | 6 | 9.9 | 60.6 | (22.1-132.0) |  | Female | 67 | 73.8 | 90.8 | (70.4-115.3) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

134

# Harwich

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 24 | 20.7 | 116.0 | (74.3-172.6) |  | Male | 21 | 11.9 | 176.3 | (109.1-269.4) |
| Female | 9 | 8.2 | 110.3 | (50.3-209.3) |  | Female | 17 | 9.4 | 181.4 | (105.6-290.5) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 3 | 3.2 | nc | (nc-nc) |  | Male | 8 | 4.0 | 201.7 | (86.8-397.4) |
| Female | 4 | 3.0 | nc | (nc-nc) |  | Female | 7 | 3.6 | 195.1 | (78.2-402.0) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 1 | 0.7 | nc | (nc-nc) |  | Male | 17 | 10.7 | 159.2 | (92.7-254.9) |
| Female | 109 | 79.3 | 137.5 | (112.9-165.9) |  | Female | 7 | 10.7 | 65.6 | (26.3-135.1) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 9 | 8.2 | 109.6 | (50.0-208.1) |
| Female | 1 | 2.2 | nc | (nc-nc) |  | Female | 5 | 4.4 | 113.5 | (36.6-264.9) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 24 | 20.2 | 119.1 | (76.3-177.2) |  |  |  |  |  |  |
| Female | 35 | 22.2 | 157.4 | (109.6-218.9) |  | Female | 6 | 6.9 | 87.1 | (31.8-189.5) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 4 | 5.0 | nc | (nc-nc) |  | Male | 7 | 7.0 | 99.9 | (40.0-205.9) |
| Female | 0 | 1.6 | nc | (nc-nc) |  | Female | 11 | 8.2 | 133.4 | (66.5-238.7) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 5 | 1.0 | 479.9 | (154.6-1119.8) |  | Male | 98 | 59.7 | 164.1 | (133.2-199.9) |
| Female | 1 | 0.9 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 10 | 10.0 | 100.0 | (47.9-183.9) |  | Male | 7 | 4.7 | 148.4 | (59.5-305.9) |
| Female | 8 | 6.6 | 121.4 | (52.3-239.3) |  | Female | 1 | 3.0 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 3 | 2.9 | nc | (nc-nc) |  | Male | 0 | 1.5 | nc | (nc-nc) |
| Female | 1 | 0.9 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 9 | 7.6 | 119.0 | (54.3-225.9) |  | Male | 5 | 3.8 | 131.4 | (42.3-306.6) |
| Female | 6 | 5.9 | 101.3 | (37.0-220.5) |  | Female | 4 | 11.4 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 4 | 6.2 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 3 | 2.6 | nc | (nc-nc) |  | Female | 20 | 18.4 | 108.5 | (66.3-167.6) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 48 | 36.8 | 130.5 | (96.2-173.0) |  | Male | 326 | 245.7 | 132.7 | (118.7-147.9) |
| Female | 42 | 42.7 | 98.3 | (70.8-132.9) |  | Female | 326 | 275.2 | 118.4 | (105.9-132.0) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

135

# Hatfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 5 | 5.1 | 98.0 | (31.6-228.6) |  | Male | 4 | 3.1 | nc | (nc-nc) |
| Female | 3 | 1.8 | nc | (nc-nc) |  | Female | 1 | 2.3 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 2 | 0.9 | nc | (nc-nc) |  | Male | 1 | 1.0 | nc | (nc-nc) |
| Female | 1 | 0.7 | nc | (nc-nc) |  | Female | 1 | 0.8 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 1 | 2.7 | nc | (nc-nc) |
| Female | 16 | 19.8 | 80.9 | (46.2-131.3) |  | Female | 2 | 2.5 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 0 | 2.3 | nc | (nc-nc) |
| Female | 0 | 0.6 | nc | (nc-nc) |  | Female | 1 | 1.0 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 5 | 5.3 | 93.7 | (30.2-218.6) |  |  |  |  |  |  |
| Female | 10 | 5.2 | 191.7 | (91.8-352.7) |  | Female | 4 | 1.7 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 1 | 1.3 | nc | (nc-nc) |  | Male | 0 | 1.8 | nc | (nc-nc) |
| Female | 0 | 0.4 | nc | (nc-nc) |  | Female | 1 | 1.9 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 1 | 0.3 | nc | (nc-nc) |  | Male | 16 | 15.5 | 103.1 | (58.9-167.4) |
| Female | 0 | 0.2 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 6 | 2.7 | 221.9 | (81.0-482.9) |  | Male | 2 | 1.2 | nc | (nc-nc) |
| Female | 5 | 1.6 | 315.5 | (101.7-736.2) |  | Female | 1 | 0.7 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 0.7 | nc | (nc-nc) |  | Male | 0 | 0.4 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 2 | 1.9 | nc | (nc-nc) |  | Male | 1 | 1.1 | nc | (nc-nc) |
| Female | 0 | 1.4 | nc | (nc-nc) |  | Female | 1 | 3.1 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 0 | 1.7 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.6 | nc | (nc-nc) |  | Female | 6 | 4.4 | 136.7 | (49.9-297.6) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 8 | 9.4 | 85.2 | (36.7-167.9) |  | Male | 61 | 63.8 | 95.7 | (73.2-122.9) |
| Female | 5 | 9.9 | 50.5 | (16.3-117.9) |  | Female | 64 | 66.1 | 96.9 | (74.6-123.7) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

136

# Haverhill

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 53 | 60.1 | 88.3 | (66.1-115.4) |  | Male | 28 | 38.7 | 72.3 | (48.1-104.6) |
| Female | 31 | 21.8 | 142.2 | (96.6-201.9) |  | Female | 19 | 31.9 | 59.6 | (35.9-93.1) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 14 | 12.2 | 115.2 | (62.9-193.3) |  | Male | 11 | 12.3 | 89.6 | (44.7-160.4) |
| Female | 12 | 10.3 | 116.3 | (60.0-203.2) |  | Female | 7 | 10.1 | 69.6 | (27.9-143.4) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 2 | 2.1 | nc | (nc-nc) |  | Male | 33 | 35.0 | 94.4 | (65.0-132.6) |
| Female | 246 | 250.4 | 98.2 | (86.4-111.3) |  | Female | 41 | 31.2 | 131.4 | (94.3-178.2) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 32 | 28.9 | 110.9 | (75.8-156.5) |
| Female | 8 | 8.9 | 90.2 | (38.9-177.8) |  | Female | 14 | 13.3 | 105.2 | (57.5-176.6) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 68 | 66.2 | 102.7 | (79.8-130.2) |  |  |  |  |  |  |
| Female | 72 | 65.8 | 109.4 | (85.6-137.7) |  | Female | 20 | 21.7 | 92.3 | (56.4-142.6) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 11 | 15.3 | 71.7 | (35.8-128.4) |  | Male | 27 | 21.5 | 125.6 | (82.7-182.7) |
| Female | 5 | 4.3 | 117.2 | (37.8-273.5) |  | Female | 24 | 22.5 | 106.5 | (68.2-158.5) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 6 | 5.0 | 118.9 | (43.4-258.8) |  | Male | 148 | 184.5 | 80.2 | (67.8-94.2) |
| Female | 3 | 4.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 33 | 33.8 | 97.8 | (67.3-137.3) |  | Male | 17 | 14.6 | 116.6 | (67.9-186.7) |
| Female | 24 | 19.7 | 121.7 | (77.9-181.1) |  | Female | 8 | 8.9 | 89.8 | (38.7-177.0) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 10 | 8.9 | 113.0 | (54.1-207.8) |  | Male | 7 | 9.5 | 73.4 | (29.4-151.2) |
| Female | 6 | 2.7 | 219.7 | (80.2-478.2) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 21 | 25.1 | 83.6 | (51.7-127.8) |  | Male | 17 | 16.0 | 106.3 | (61.9-170.2) |
| Female | 18 | 18.7 | 96.2 | (57.0-152.0) |  | Female | 57 | 49.2 | 115.9 | (87.8-150.2) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 17 | 21.1 | 80.7 | (47.0-129.2) |  |  |  |  |  |  |
| Female | 6 | 7.3 | 82.7 | (30.2-180.0) |  | Female | 62 | 55.8 | 111.2 | (85.3-142.6) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 105 | 104.3 | 100.6 | (82.3-121.8) |  | Male | 711 | 779.2 | 91.2 | (84.7-98.2) |
| Female | 138 | 112.5 | 122.7 | (103.0-144.9) |  | Female | 888 | 839.3 | 105.8 | (99.0-113.0) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

137

# Hawley

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 1 | 0.8 | nc | (nc-nc) |  | Male | 0 | 0.5 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 0 | 0.3 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 0 | 0.2 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 0 | 0.1 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.0 | nc | (nc-nc) |  | Male | 0 | 0.4 | nc | (nc-nc) |
| Female | 3 | 2.1 | nc | (nc-nc) |  | Female | 0 | 0.2 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 0 | 0.3 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 0 | 0.1 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 0 | 0.8 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.5 | nc | (nc-nc) |  | Female | 0 | 0.2 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 1 | 0.3 | nc | (nc-nc) |
| Female | 0 | 0.0 | nc | (nc-nc) |  | Female | 0 | 0.2 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.0 | nc | (nc-nc) |  | Male | 1 | 2.5 | nc | (nc-nc) |
| Female | 0 | 0.0 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 0 | 0.4 | nc | (nc-nc) |  | Male | 0 | 0.2 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 0 | 0.1 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 0 | 0.1 | nc | (nc-nc) |
| Female | 0 | 0.0 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  | Male | 0 | 0.2 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 0 | 0.4 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 0 | 0.5 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 1 | 1.4 | nc | (nc-nc) |  | Male | 4 | 9.7 | nc | (nc-nc) |
| Female | 0 | 0.9 | nc | (nc-nc) |  | Female | 3 | 6.8 | nc | (nc-nc) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

138

# Heath

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 2 | 0.9 | nc | (nc-nc) |  | Male | 0 | 0.6 | nc | (nc-nc) |
| Female | 1 | 0.3 | nc | (nc-nc) |  | Female | 0 | 0.4 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 0 | 0.2 | nc | (nc-nc) |
| Female | 1 | 0.1 | nc | (nc-nc) |  | Female | 0 | 0.1 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.0 | nc | (nc-nc) |  | Male | 0 | 0.5 | nc | (nc-nc) |
| Female | 2 | 3.4 | nc | (nc-nc) |  | Female | 0 | 0.4 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 0 | 0.5 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 0 | 0.2 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 0 | 1.0 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 1 | 0.7 | nc | (nc-nc) |  | Female | 0 | 0.3 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  | Male | 0 | 0.3 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 0 | 0.3 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 5 | 3.6 | 139.8 | (45.0-326.2) |
| Female | 1 | 0.0 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 0 | 0.6 | nc | (nc-nc) |  | Male | 0 | 0.2 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  | Female | 0 | 0.1 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 0 | 0.1 | nc | (nc-nc) |
| Female | 0 | 0.0 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 1 | 0.4 | nc | (nc-nc) |  | Male | 1 | 0.2 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 1 | 0.5 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 3 | 0.9 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 4 | 1.7 | nc | (nc-nc) |  | Male | 14 | 12.7 | 110.2 | (60.2-185.0) |
| Female | 1 | 1.5 | nc | (nc-nc) |  | Female | 11 | 10.7 | 103.0 | (51.3-184.2) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

139

# Hingham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 29 | 30.7 | 94.5 | (63.2-135.7) |  | Male | 34 | 18.2 | 187.3 | (129.7-261.7) |
| Female | 9 | 11.5 | 78.3 | (35.7-148.6) |  | Female | 29 | 13.9 | 208.8 | (139.8-299.9) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 7 | 5.2 | 134.1 | (53.7-276.3) |  | Male | 7 | 5.8 | 120.4 | (48.2-248.1) |
| Female | 6 | 4.5 | 133.2 | (48.6-289.9) |  | Female | 5 | 5.1 | 98.3 | (31.7-229.3) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 1 | 1.0 | nc | (nc-nc) |  | Male | 13 | 16.3 | 79.7 | (42.4-136.3) |
| Female | 113 | 113.5 | 99.5 | (82.0-119.7) |  | Female | 25 | 15.3 | 163.5 | (105.8-241.4) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 17 | 12.7 | 133.6 | (77.8-214.0) |
| Female | 3 | 3.4 | nc | (nc-nc) |  | Female | 5 | 6.3 | 79.0 | (25.5-184.3) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 31 | 31.5 | 98.3 | (66.8-139.6) |  |  |  |  |  |  |
| Female | 35 | 33.2 | 105.5 | (73.5-146.8) |  | Female | 9 | 9.9 | 90.8 | (41.5-172.5) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 3 | 7.3 | nc | (nc-nc) |  | Male | 8 | 10.5 | 75.9 | (32.7-149.6) |
| Female | 7 | 2.2 | 318.8 | (127.7-656.9) |  | Female | 11 | 11.8 | 93.2 | (46.4-166.7) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 2 | 1.7 | nc | (nc-nc) |  | Male | 96 | 84.8 | 113.2 | (91.7-138.2) |
| Female | 1 | 1.4 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 14 | 15.2 | 92.3 | (50.4-154.9) |  | Male | 13 | 7.1 | 182.5 | (97.1-312.2) |
| Female | 8 | 9.3 | 85.7 | (36.9-168.9) |  | Female | 1 | 4.5 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 2 | 4.1 | nc | (nc-nc) |  | Male | 5 | 2.8 | 181.2 | (58.4-422.9) |
| Female | 0 | 1.3 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 15 | 11.9 | 126.4 | (70.7-208.4) |  | Male | 4 | 6.3 | nc | (nc-nc) |
| Female | 14 | 8.9 | 157.7 | (86.2-264.7) |  | Female | 30 | 18.0 | 166.6 | (112.4-237.8) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 3 | 9.5 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 1 | 3.6 | nc | (nc-nc) |  | Female | 20 | 25.3 | 79.1 | (48.3-122.1) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 29 | 52.7 | 55.0 | (36.8-79.0) |  | Male | 365 | 366.6 | 99.6 | (89.6-110.3) |
| Female | 40 | 58.5 | 68.4 | (48.8-93.1) |  | Female | 402 | 395.6 | 101.6 | (91.9-112.1) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

140

# Hinsdale

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 3 | 2.9 | nc | (nc-nc) |  | Male | 1 | 1.8 | nc | (nc-nc) |
| Female | 1 | 0.8 | nc | (nc-nc) |  | Female | 1 | 1.1 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 1 | 0.5 | nc | (nc-nc) |  | Male | 1 | 0.6 | nc | (nc-nc) |
| Female | 1 | 0.4 | nc | (nc-nc) |  | Female | 0 | 0.4 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 2 | 1.6 | nc | (nc-nc) |
| Female | 17 | 9.6 | 177.0 | (103.0-283.4) |  | Female | 3 | 1.1 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 1 | 1.4 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  | Female | 1 | 0.5 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 3 | 3.2 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 4 | 2.5 | nc | (nc-nc) |  | Female | 1 | 0.8 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 1 | 0.7 | nc | (nc-nc) |  | Male | 2 | 1.0 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 0 | 0.8 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 8 | 9.1 | 88.0 | (37.9-173.4) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 2 | 1.6 | nc | (nc-nc) |  | Male | 1 | 0.7 | nc | (nc-nc) |
| Female | 0 | 0.7 | nc | (nc-nc) |  | Female | 0 | 0.3 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 0.4 | nc | (nc-nc) |  | Male | 0 | 0.3 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 0 | 1.1 | nc | (nc-nc) |  | Male | 0 | 0.7 | nc | (nc-nc) |
| Female | 1 | 0.7 | nc | (nc-nc) |  | Female | 4 | 1.7 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 0 | 1.1 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.3 | nc | (nc-nc) |  | Female | 1 | 2.1 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 7 | 5.0 | 141.4 | (56.6-291.3) |  | Male | 35 | 37.1 | 94.3 | (65.7-131.2) |
| Female | 6 | 4.2 | 144.4 | (52.7-314.2) |  | Female | 43 | 31.3 | 137.6 | (99.6-185.3) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

141

# Holbrook

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 17 | 12.8 | 132.4 | (77.1-212.0) |  | Male | 5 | 8.3 | 60.2 | (19.4-140.6) |
| Female | 8 | 4.4 | 180.0 | (77.5-354.6) |  | Female | 3 | 6.3 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 3 | 2.5 | nc | (nc-nc) |  | Male | 2 | 2.7 | nc | (nc-nc) |
| Female | 5 | 1.9 | 257.7 | (83.1-601.4) |  | Female | 6 | 2.0 | 292.7 | (106.9-637.2) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.4 | nc | (nc-nc) |  | Male | 10 | 7.4 | 135.9 | (65.0-249.9) |
| Female | 58 | 52.0 | 111.5 | (84.6-144.1) |  | Female | 8 | 6.3 | 127.5 | (54.9-251.2) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 6 | 6.1 | 97.9 | (35.7-213.0) |
| Female | 3 | 1.7 | nc | (nc-nc) |  | Female | 1 | 2.7 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 22 | 14.0 | 157.1 | (98.4-237.8) |  |  |  |  |  |  |
| Female | 20 | 13.1 | 152.7 | (93.2-235.8) |  | Female | 9 | 4.4 | 203.4 | (92.8-386.2) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 6 | 3.3 | 181.7 | (66.3-395.4) |  | Male | 6 | 4.6 | 130.9 | (47.8-284.9) |
| Female | 0 | 0.9 | nc | (nc-nc) |  | Female | 5 | 4.5 | 111.5 | (35.9-260.2) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 2 | 1.0 | nc | (nc-nc) |  | Male | 51 | 38.8 | 131.5 | (97.9-172.9) |
| Female | 2 | 0.7 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 15 | 7.1 | 210.2 | (117.6-346.8) |  | Male | 2 | 3.1 | nc | (nc-nc) |
| Female | 4 | 4.1 | nc | (nc-nc) |  | Female | 1 | 1.8 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 1 | 1.9 | nc | (nc-nc) |  | Male | 1 | 1.8 | nc | (nc-nc) |
| Female | 1 | 0.6 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 7 | 5.1 | 136.1 | (54.5-280.5) |  | Male | 0 | 3.3 | nc | (nc-nc) |
| Female | 7 | 3.6 | 197.1 | (78.9-406.0) |  | Female | 8 | 9.4 | 84.8 | (36.5-167.1) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 5 | 4.5 | 110.5 | (35.6-258.0) |  |  |  |  |  |  |
| Female | 1 | 1.5 | nc | (nc-nc) |  | Female | 9 | 11.6 | 77.9 | (35.5-147.9) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 20 | 22.9 | 87.2 | (53.2-134.7) |  | Male | 194 | 165.3 | 117.4 | (101.4-135.1) |
| Female | 34 | 24.1 | 141.1 | (97.7-197.1) |  | Female | 203 | 170.9 | 118.8 | (103.0-136.3) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

142

# Holden

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 15 | 19.1 | 78.6 | (43.9-129.6) |  | Male | 22 | 12.3 | 178.2 | (111.6-269.8) |
| Female | 11 | 6.9 | 159.6 | (79.6-285.6) |  | Female | 11 | 9.6 | 114.2 | (56.9-204.4) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 2 | 3.8 | nc | (nc-nc) |  | Male | 7 | 4.0 | 175.6 | (70.3-361.7) |
| Female | 6 | 3.1 | 194.4 | (71.0-423.2) |  | Female | 2 | 3.2 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 1 | 0.7 | nc | (nc-nc) |  | Male | 13 | 11.1 | 116.9 | (62.2-199.9) |
| Female | 94 | 77.8 | 120.8 | (97.6-147.8) |  | Female | 8 | 9.8 | 81.8 | (35.2-161.1) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 13 | 9.5 | 137.5 | (73.2-235.2) |
| Female | 1 | 2.7 | nc | (nc-nc) |  | Female | 5 | 4.1 | 121.1 | (39.0-282.6) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 15 | 21.2 | 70.8 | (39.6-116.8) |  |  |  |  |  |  |
| Female | 19 | 20.6 | 92.3 | (55.5-144.1) |  | Female | 7 | 6.7 | 104.6 | (41.9-215.5) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 6 | 5.0 | 120.0 | (43.8-261.1) |  | Male | 11 | 6.9 | 158.4 | (79.0-283.4) |
| Female | 0 | 1.3 | nc | (nc-nc) |  | Female | 6 | 7.0 | 85.6 | (31.3-186.3) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 2 | 1.4 | nc | (nc-nc) |  | Male | 62 | 60.9 | 101.7 | (78.0-130.4) |
| Female | 1 | 1.2 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 7 | 10.9 | 64.2 | (25.7-132.3) |  | Male | 2 | 4.7 | nc | (nc-nc) |
| Female | 6 | 6.1 | 98.1 | (35.8-213.5) |  | Female | 5 | 2.8 | 178.8 | (57.6-417.3) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 3 | 2.9 | nc | (nc-nc) |  | Male | 1 | 2.5 | nc | (nc-nc) |
| Female | 0 | 0.9 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 7 | 7.8 | 89.2 | (35.7-183.7) |  | Male | 4 | 5.0 | nc | (nc-nc) |
| Female | 5 | 5.6 | 89.0 | (28.7-207.6) |  | Female | 11 | 14.5 | 76.0 | (37.9-136.0) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 5 | 6.9 | 72.1 | (23.2-168.3) |  |  |  |  |  |  |
| Female | 4 | 2.3 | nc | (nc-nc) |  | Female | 30 | 17.2 | 174.0 | (117.3-248.3) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 24 | 33.8 | 71.1 | (45.5-105.8) |  | Male | 242 | 250.6 | 96.6 | (84.8-109.5) |
| Female | 29 | 35.9 | 80.9 | (54.2-116.2) |  | Female | 289 | 260.3 | 111.0 | (98.6-124.6) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

143

# Holland

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 1 | 3.1 | nc | (nc-nc) |  | Male | 2 | 2.1 | nc | (nc-nc) |
| Female | 3 | 0.7 | nc | (nc-nc) |  | Female | 1 | 1.2 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 0.6 | nc | (nc-nc) |  | Male | 2 | 0.7 | nc | (nc-nc) |
| Female | 0 | 0.4 | nc | (nc-nc) |  | Female | 0 | 0.4 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 0 | 1.8 | nc | (nc-nc) |
| Female | 8 | 10.5 | 76.0 | (32.7-149.8) |  | Female | 2 | 1.2 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 0 | 1.6 | nc | (nc-nc) |
| Female | 0 | 0.4 | nc | (nc-nc) |  | Female | 0 | 0.5 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 1 | 3.4 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 1 | 2.3 | nc | (nc-nc) |  | Female | 0 | 0.9 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 1 | 0.9 | nc | (nc-nc) |  | Male | 2 | 1.1 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 0 | 0.7 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 1 | 0.2 | nc | (nc-nc) |  | Male | 5 | 10.3 | 48.4 | (15.6-112.9) |
| Female | 0 | 0.2 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 2 | 1.9 | nc | (nc-nc) |  | Male | 1 | 0.8 | nc | (nc-nc) |
| Female | 0 | 0.8 | nc | (nc-nc) |  | Female | 0 | 0.3 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 0.5 | nc | (nc-nc) |  | Male | 2 | 0.4 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 1 | 1.3 | nc | (nc-nc) |  | Male | 1 | 0.8 | nc | (nc-nc) |
| Female | 2 | 0.6 | nc | (nc-nc) |  | Female | 4 | 2.1 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 0 | 1.2 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.3 | nc | (nc-nc) |  | Female | 3 | 2.3 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 5 | 5.9 | 85.4 | (27.5-199.2) |  | Male | 28 | 42.0 | 66.6 | (44.3-96.3) |
| Female | 6 | 4.1 | 145.1 | (53.0-315.9) |  | Female | 34 | 32.4 | 104.8 | (72.6-146.5) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

144

# Holliston

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 20 | 13.8 | 145.2 | (88.6-224.2) |  | Male | 11 | 9.2 | 119.9 | (59.8-214.6) |
| Female | 3 | 5.0 | nc | (nc-nc) |  | Female | 9 | 7.3 | 122.7 | (56.0-232.9) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 7 | 2.9 | 239.7 | (96.0-493.8) |  | Male | 5 | 3.0 | 169.0 | (54.5-394.3) |
| Female | 2 | 2.4 | nc | (nc-nc) |  | Female | 0 | 2.4 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.5 | nc | (nc-nc) |  | Male | 10 | 8.3 | 120.9 | (57.9-222.4) |
| Female | 77 | 62.2 | 123.8 | (97.7-154.7) |  | Female | 5 | 7.3 | 68.9 | (22.2-160.8) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 8 | 7.3 | 110.2 | (47.4-217.1) |
| Female | 3 | 2.1 | nc | (nc-nc) |  | Female | 5 | 3.2 | 158.1 | (50.9-368.9) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 15 | 15.7 | 95.6 | (53.4-157.6) |  |  |  |  |  |  |
| Female | 14 | 15.1 | 93.0 | (50.8-156.0) |  | Female | 3 | 5.2 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 4 | 3.7 | nc | (nc-nc) |  | Male | 3 | 5.1 | nc | (nc-nc) |
| Female | 1 | 1.0 | nc | (nc-nc) |  | Female | 3 | 5.1 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 1 | 1.1 | nc | (nc-nc) |  | Male | 53 | 47.2 | 112.4 | (84.2-147.0) |
| Female | 0 | 0.8 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 10 | 8.4 | 119.5 | (57.2-219.7) |  | Male | 1 | 3.4 | nc | (nc-nc) |
| Female | 4 | 4.8 | nc | (nc-nc) |  | Female | 1 | 2.0 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 3 | 2.2 | nc | (nc-nc) |  | Male | 5 | 1.9 | 265.4 | (85.5-619.4) |
| Female | 0 | 0.7 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 6 | 5.9 | 102.5 | (37.4-223.2) |  | Male | 5 | 3.9 | 128.5 | (41.4-300.0) |
| Female | 4 | 4.1 | nc | (nc-nc) |  | Female | 14 | 11.4 | 123.0 | (67.2-206.4) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 3 | 5.2 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 4 | 1.7 | nc | (nc-nc) |  | Female | 19 | 13.9 | 136.3 | (82.0-212.9) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 15 | 24.8 | 60.4 | (33.8-99.7) |  | Male | 205 | 188.1 | 109.0 | (94.6-125.0) |
| Female | 23 | 27.0 | 85.2 | (54.0-127.8) |  | Female | 206 | 199.9 | 103.0 | (89.5-118.1) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

145

# Holyoke

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 29 | 37.8 | 76.7 | (51.4-110.2) |  | Male | 15 | 23.5 | 63.7 | (35.6-105.1) |
| Female | 13 | 15.6 | 83.2 | (44.2-142.2) |  | Female | 11 | 21.1 | 52.2 | (26.0-93.4) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 11 | 7.5 | 145.9 | (72.7-261.0) |  | Male | 4 | 7.4 | nc | (nc-nc) |
| Female | 5 | 6.9 | 72.9 | (23.5-170.1) |  | Female | 1 | 7.0 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 1 | 1.3 | nc | (nc-nc) |  | Male | 17 | 21.4 | 79.4 | (46.2-127.2) |
| Female | 128 | 162.9 | 78.6 | (65.5-93.4) |  | Female | 18 | 21.4 | 84.1 | (49.8-132.9) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 27 | 16.7 | 161.5 | (106.4-235.0) |
| Female | 7 | 5.6 | 124.6 | (49.9-256.7) |  | Female | 7 | 8.9 | 78.9 | (31.6-162.6) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 41 | 40.6 | 101.0 | (72.5-137.0) |  |  |  |  |  |  |
| Female | 45 | 45.9 | 97.9 | (71.4-131.1) |  | Female | 13 | 14.2 | 91.4 | (48.6-156.4) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 6 | 9.1 | 66.0 | (24.1-143.7) |  | Male | 14 | 13.2 | 106.0 | (57.9-177.9) |
| Female | 0 | 3.0 | nc | (nc-nc) |  | Female | 22 | 16.0 | 137.1 | (85.9-207.6) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 4 | 3.2 | nc | (nc-nc) |  | Male | 95 | 105.2 | 90.3 | (73.1-110.4) |
| Female | 7 | 2.8 | 253.1 | (101.4-521.5) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 21 | 19.8 | 106.2 | (65.7-162.3) |  | Male | 7 | 9.0 | 77.9 | (31.2-160.5) |
| Female | 10 | 13.3 | 75.4 | (36.1-138.7) |  | Female | 9 | 6.2 | 144.2 | (65.8-273.7) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 8 | 5.2 | 154.2 | (66.4-303.8) |  | Male | 1 | 6.0 | nc | (nc-nc) |
| Female | 3 | 1.8 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 10 | 15.8 | 63.2 | (30.3-116.3) |  | Male | 1 | 9.3 | nc | (nc-nc) |
| Female | 8 | 13.0 | 61.7 | (26.5-121.5) |  | Female | 24 | 31.1 | 77.2 | (49.4-114.8) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 25 | 12.3 | 202.9 | (131.3-299.6) |  |  |  |  |  |  |
| Female | 6 | 4.9 | 121.5 | (44.4-264.6) |  | Female | 43 | 35.3 | 121.7 | (88.1-163.9) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 75 | 64.2 | 116.8 | (91.8-146.4) |  | Male | 464 | 469.3 | 98.9 | (90.1-108.3) |
| Female | 76 | 79.7 | 95.3 | (75.1-119.3) |  | Female | 511 | 564.6 | 90.5 | (82.8-98.7) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

146

# Hopedale

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 6 | 6.1 | 98.2 | (35.9-213.7) |  | Male | 3 | 3.8 | nc | (nc-nc) |
| Female | 3 | 2.2 | nc | (nc-nc) |  | Female | 2 | 3.1 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 1.2 | nc | (nc-nc) |  | Male | 0 | 1.2 | nc | (nc-nc) |
| Female | 0 | 1.0 | nc | (nc-nc) |  | Female | 2 | 1.0 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 3 | 3.5 | nc | (nc-nc) |
| Female | 26 | 24.9 | 104.5 | (68.3-153.2) |  | Female | 1 | 3.2 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 2 | 2.9 | nc | (nc-nc) |
| Female | 1 | 0.9 | nc | (nc-nc) |  | Female | 1 | 1.3 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 6 | 6.9 | 87.0 | (31.8-189.4) |  |  |  |  |  |  |
| Female | 8 | 6.9 | 115.2 | (49.6-227.1) |  | Female | 1 | 2.1 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 3 | 1.5 | nc | (nc-nc) |  | Male | 2 | 2.2 | nc | (nc-nc) |
| Female | 0 | 0.4 | nc | (nc-nc) |  | Female | 0 | 2.3 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.5 | nc | (nc-nc) |  | Male | 22 | 17.1 | 128.8 | (80.7-195.0) |
| Female | 1 | 0.4 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 2 | 3.3 | nc | (nc-nc) |  | Male | 3 | 1.5 | nc | (nc-nc) |
| Female | 3 | 1.9 | nc | (nc-nc) |  | Female | 1 | 1.0 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 1 | 0.8 | nc | (nc-nc) |  | Male | 1 | 0.8 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 3 | 2.6 | nc | (nc-nc) |  | Male | 3 | 1.5 | nc | (nc-nc) |
| Female | 1 | 1.9 | nc | (nc-nc) |  | Female | 8 | 4.8 | 167.7 | (72.2-330.4) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 3 | 2.1 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.7 | nc | (nc-nc) |  | Female | 6 | 5.2 | 114.6 | (41.9-249.5) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 13 | 10.0 | 130.3 | (69.3-222.8) |  | Male | 86 | 76.2 | 112.8 | (90.2-139.3) |
| Female | 11 | 11.1 | 98.9 | (49.3-177.0) |  | Female | 82 | 83.8 | 97.8 | (77.8-121.4) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

147

# Hopkinton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 11 | 11.8 | 93.1 | (46.4-166.6) |  | Male | 9 | 8.5 | 105.5 | (48.1-200.2) |
| Female | 9 | 4.3 | 211.4 | (96.4-401.2) |  | Female | 11 | 7.1 | 155.5 | (77.5-278.2) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 5 | 2.9 | 172.7 | (55.6-403.0) |  | Male | 2 | 2.7 | nc | (nc-nc) |
| Female | 3 | 2.4 | nc | (nc-nc) |  | Female | 0 | 2.1 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.4 | nc | (nc-nc) |  | Male | 7 | 7.7 | 91.1 | (36.5-187.7) |
| Female | 58 | 59.6 | 97.4 | (73.9-125.9) |  | Female | 6 | 6.6 | 91.3 | (33.3-198.7) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 8 | 7.1 | 112.8 | (48.6-222.2) |
| Female | 4 | 2.2 | nc | (nc-nc) |  | Female | 1 | 2.9 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 10 | 14.6 | 68.6 | (32.8-126.1) |  |  |  |  |  |  |
| Female | 12 | 13.5 | 88.6 | (45.7-154.8) |  | Female | 3 | 4.9 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 2 | 3.4 | nc | (nc-nc) |  | Male | 5 | 4.5 | 110.2 | (35.5-257.1) |
| Female | 1 | 0.8 | nc | (nc-nc) |  | Female | 7 | 4.3 | 162.6 | (65.1-335.0) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 1.1 | nc | (nc-nc) |  | Male | 53 | 42.9 | 123.7 | (92.6-161.7) |
| Female | 3 | 0.9 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 4 | 8.1 | nc | (nc-nc) |  | Male | 4 | 3.1 | nc | (nc-nc) |
| Female | 0 | 4.4 | nc | (nc-nc) |  | Female | 0 | 1.8 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 3 | 2.0 | nc | (nc-nc) |  | Male | 3 | 2.1 | nc | (nc-nc) |
| Female | 0 | 0.6 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 2 | 5.4 | nc | (nc-nc) |  | Male | 9 | 4.1 | 220.3 | (100.5-418.3) |
| Female | 1 | 3.9 | nc | (nc-nc) |  | Female | 16 | 12.1 | 132.1 | (75.5-214.6) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 4 | 4.9 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 1.5 | nc | (nc-nc) |  | Female | 12 | 12.7 | 94.4 | (48.7-165.0) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 15 | 21.7 | 69.1 | (38.7-114.0) |  | Male | 166 | 172.5 | 96.2 | (82.2-112.0) |
| Female | 22 | 23.3 | 94.3 | (59.1-142.8) |  | Female | 179 | 185.6 | 96.5 | (82.8-111.7) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

148

# Hubbardston

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 3 | 4.3 | nc | (nc-nc) |  | Male | 1 | 2.9 | nc | (nc-nc) |
| Female | 1 | 1.2 | nc | (nc-nc) |  | Female | 2 | 2.1 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 1 | 0.9 | nc | (nc-nc) |  | Male | 1 | 0.9 | nc | (nc-nc) |
| Female | 1 | 0.7 | nc | (nc-nc) |  | Female | 1 | 0.6 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 5 | 2.7 | 188.4 | (60.7-439.6) |
| Female | 16 | 17.8 | 89.8 | (51.3-145.8) |  | Female | 2 | 1.9 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 0 | 2.4 | nc | (nc-nc) |
| Female | 0 | 0.6 | nc | (nc-nc) |  | Female | 6 | 0.8 | 708.2 | (258.6-1541.5) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 0 | 5.1 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 5 | 3.9 | 129.4 | (41.7-302.0) |  | Female | 2 | 1.5 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 1 | 1.2 | nc | (nc-nc) |  | Male | 1 | 1.6 | nc | (nc-nc) |
| Female | 1 | 0.2 | nc | (nc-nc) |  | Female | 2 | 1.2 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.4 | nc | (nc-nc) |  | Male | 12 | 14.7 | 81.6 | (42.1-142.5) |
| Female | 1 | 0.3 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 3 | 2.7 | nc | (nc-nc) |  | Male | 4 | 1.1 | nc | (nc-nc) |
| Female | 2 | 1.3 | nc | (nc-nc) |  | Female | 0 | 0.5 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 0.7 | nc | (nc-nc) |  | Male | 0 | 0.6 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 2 | 1.8 | nc | (nc-nc) |  | Male | 1 | 1.3 | nc | (nc-nc) |
| Female | 0 | 1.1 | nc | (nc-nc) |  | Female | 5 | 3.6 | 138.7 | (44.7-323.6) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 1 | 1.6 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.4 | nc | (nc-nc) |  | Female | 2 | 3.9 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 4 | 7.7 | nc | (nc-nc) |  | Male | 45 | 59.5 | 75.7 | (55.2-101.3) |
| Female | 8 | 6.5 | 122.2 | (52.6-240.9) |  | Female | 60 | 54.2 | 110.7 | (84.4-142.5) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

149

# Hudson

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 23 | 22.0 | 104.7 | (66.3-157.1) |  | Male | 13 | 14.2 | 91.7 | (48.8-156.8) |
| Female | 8 | 8.2 | 97.3 | (41.9-191.8) |  | Female | 10 | 11.2 | 89.5 | (42.9-164.7) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 7 | 4.3 | 162.3 | (65.0-334.4) |  | Male | 4 | 4.6 | nc | (nc-nc) |
| Female | 3 | 3.6 | nc | (nc-nc) |  | Female | 3 | 3.7 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 2 | 0.8 | nc | (nc-nc) |  | Male | 7 | 12.7 | 55.2 | (22.1-113.8) |
| Female | 89 | 92.8 | 95.9 | (77.0-118.0) |  | Female | 11 | 11.4 | 96.8 | (48.3-173.3) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 13 | 10.8 | 120.3 | (64.0-205.8) |
| Female | 2 | 3.0 | nc | (nc-nc) |  | Female | 6 | 4.8 | 124.7 | (45.5-271.5) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 26 | 23.9 | 108.8 | (71.1-159.4) |  |  |  |  |  |  |
| Female | 34 | 23.2 | 146.6 | (101.5-204.8) |  | Female | 8 | 7.9 | 101.4 | (43.7-199.8) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 4 | 5.8 | nc | (nc-nc) |  | Male | 1 | 7.9 | nc | (nc-nc) |
| Female | 1 | 1.7 | nc | (nc-nc) |  | Female | 7 | 8.3 | 84.8 | (34.0-174.7) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 1.6 | nc | (nc-nc) |  | Male | 69 | 73.5 | 93.8 | (73.0-118.8) |
| Female | 2 | 1.3 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 8 | 12.8 | 62.6 | (27.0-123.3) |  | Male | 3 | 5.3 | nc | (nc-nc) |
| Female | 10 | 7.4 | 134.5 | (64.4-247.4) |  | Female | 5 | 3.1 | 159.1 | (51.3-371.4) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 1 | 3.4 | nc | (nc-nc) |  | Male | 3 | 2.9 | nc | (nc-nc) |
| Female | 0 | 1.0 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 6 | 8.9 | 67.4 | (24.6-146.7) |  | Male | 6 | 5.8 | 103.8 | (37.9-226.0) |
| Female | 1 | 6.5 | nc | (nc-nc) |  | Female | 28 | 16.5 | 170.1 | (113.0-245.9) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 5 | 7.7 | 65.0 | (20.9-151.6) |  |  |  |  |  |  |
| Female | 2 | 2.7 | nc | (nc-nc) |  | Female | 22 | 20.8 | 105.6 | (66.1-159.9) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 28 | 40.4 | 69.3 | (46.1-100.2) |  | Male | 251 | 291.6 | 86.1 | (75.8-97.4) |
| Female | 34 | 44.8 | 75.8 | (52.5-106.0) |  | Female | 309 | 308.1 | 100.3 | (89.4-112.1) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

150

# Hull

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 16 | 13.8 | 115.8 | (66.1-188.0) |  | Male | 17 | 8.8 | 193.1 | (112.4-309.2) |
| Female | 7 | 5.4 | 130.7 | (52.3-269.2) |  | Female | 14 | 7.1 | 195.8 | (107.0-328.6) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 3 | 2.5 | nc | (nc-nc) |  | Male | 2 | 2.9 | nc | (nc-nc) |
| Female | 3 | 2.2 | nc | (nc-nc) |  | Female | 2 | 2.5 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 1 | 0.5 | nc | (nc-nc) |  | Male | 3 | 7.8 | nc | (nc-nc) |
| Female | 60 | 60.9 | 98.5 | (75.1-126.8) |  | Female | 12 | 7.4 | 161.1 | (83.2-281.5) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 6 | 6.8 | 88.8 | (32.4-193.3) |
| Female | 4 | 1.8 | nc | (nc-nc) |  | Female | 7 | 3.2 | 220.5 | (88.3-454.3) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 15 | 14.7 | 102.3 | (57.2-168.8) |  |  |  |  |  |  |
| Female | 15 | 15.1 | 99.5 | (55.7-164.2) |  | Female | 6 | 5.2 | 115.1 | (42.0-250.5) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 2 | 3.7 | nc | (nc-nc) |  | Male | 5 | 5.0 | 99.5 | (32.1-232.1) |
| Female | 1 | 1.1 | nc | (nc-nc) |  | Female | 6 | 5.3 | 112.8 | (41.2-245.6) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 4 | 0.8 | nc | (nc-nc) |  | Male | 43 | 46.9 | 91.8 | (66.4-123.6) |
| Female | 0 | 0.7 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 11 | 7.8 | 140.6 | (70.1-251.6) |  | Male | 3 | 3.4 | nc | (nc-nc) |
| Female | 6 | 4.9 | 123.3 | (45.0-268.5) |  | Female | 1 | 2.0 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 4 | 2.2 | nc | (nc-nc) |  | Male | 5 | 1.3 | 385.4 | (124.2-899.4) |
| Female | 2 | 0.7 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 4 | 5.4 | nc | (nc-nc) |  | Male | 4 | 3.3 | nc | (nc-nc) |
| Female | 2 | 4.1 | nc | (nc-nc) |  | Female | 7 | 10.1 | 69.4 | (27.8-143.0) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 13 | 5.1 | 253.2 | (134.7-433.1) |  |  |  |  |  |  |
| Female | 0 | 1.8 | nc | (nc-nc) |  | Female | 17 | 14.2 | 119.8 | (69.8-191.8) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 22 | 25.6 | 86.0 | (53.9-130.2) |  | Male | 193 | 182.3 | 105.9 | (91.5-121.9) |
| Female | 33 | 29.6 | 111.6 | (76.8-156.8) |  | Female | 218 | 200.6 | 108.7 | (94.7-124.1) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

151

# Huntington

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 3 | 2.1 | nc | (nc-nc) |  | Male | 2 | 1.4 | nc | (nc-nc) |
| Female | 0 | 0.7 | nc | (nc-nc) |  | Female | 1 | 1.0 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 1 | 0.5 | nc | (nc-nc) |  | Male | 0 | 0.5 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  | Female | 0 | 0.3 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 1 | 1.3 | nc | (nc-nc) |
| Female | 10 | 9.2 | 108.7 | (52.0-199.9) |  | Female | 3 | 1.0 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 1 | 1.2 | nc | (nc-nc) |
| Female | 1 | 0.3 | nc | (nc-nc) |  | Female | 0 | 0.5 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 2 | 2.4 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 3 | 2.0 | nc | (nc-nc) |  | Female | 2 | 0.8 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 2 | 0.6 | nc | (nc-nc) |  | Male | 0 | 0.8 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 0 | 0.7 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 4 | 7.7 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 3 | 1.4 | nc | (nc-nc) |  | Male | 0 | 0.5 | nc | (nc-nc) |
| Female | 1 | 0.7 | nc | (nc-nc) |  | Female | 0 | 0.3 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 3 | 0.3 | nc | (nc-nc) |  | Male | 0 | 0.3 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 1 | 0.9 | nc | (nc-nc) |  | Male | 0 | 0.6 | nc | (nc-nc) |
| Female | 1 | 0.6 | nc | (nc-nc) |  | Female | 4 | 1.7 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 1 | 0.8 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 1 | 2.2 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 6 | 3.9 | 154.5 | (56.4-336.3) |  | Male | 33 | 29.7 | 111.0 | (76.4-155.9) |
| Female | 5 | 4.1 | 120.8 | (38.9-281.9) |  | Female | 33 | 29.1 | 113.5 | (78.1-159.5) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

152

# Ipswich

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 17 | 17.8 | 95.4 | (55.6-152.8) |  | Male | 17 | 11.3 | 150.4 | (87.6-240.8) |
| Female | 9 | 6.7 | 133.6 | (61.0-253.6) |  | Female | 8 | 8.6 | 93.4 | (40.2-183.9) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 2 | 3.3 | nc | (nc-nc) |  | Male | 1 | 3.7 | nc | (nc-nc) |
| Female | 2 | 2.7 | nc | (nc-nc) |  | Female | 1 | 3.1 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 1 | 0.6 | nc | (nc-nc) |  | Male | 13 | 10.1 | 128.4 | (68.3-219.6) |
| Female | 88 | 72.2 | 121.9 | (97.7-150.1) |  | Female | 8 | 9.3 | 86.4 | (37.2-170.2) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 9 | 8.6 | 104.6 | (47.7-198.5) |
| Female | 2 | 2.2 | nc | (nc-nc) |  | Female | 7 | 3.9 | 180.7 | (72.4-372.4) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 17 | 19.3 | 87.9 | (51.2-140.7) |  |  |  |  |  |  |
| Female | 16 | 19.3 | 82.7 | (47.2-134.3) |  | Female | 5 | 6.2 | 80.6 | (26.0-188.2) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 10 | 4.7 | 214.5 | (102.7-394.5) |  | Male | 7 | 6.4 | 108.6 | (43.5-223.8) |
| Female | 3 | 1.3 | nc | (nc-nc) |  | Female | 6 | 6.9 | 87.5 | (31.9-190.4) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 1.1 | nc | (nc-nc) |  | Male | 66 | 58.0 | 113.8 | (88.0-144.8) |
| Female | 1 | 0.8 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 6 | 10.0 | 59.9 | (21.9-130.4) |  | Male | 3 | 4.3 | nc | (nc-nc) |
| Female | 6 | 5.7 | 104.5 | (38.1-227.4) |  | Female | 6 | 2.6 | 228.7 | (83.5-497.8) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 2 | 2.8 | nc | (nc-nc) |  | Male | 4 | 1.8 | nc | (nc-nc) |
| Female | 0 | 0.8 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 4 | 7.0 | nc | (nc-nc) |  | Male | 4 | 4.3 | nc | (nc-nc) |
| Female | 5 | 5.1 | 97.7 | (31.5-228.0) |  | Female | 14 | 11.5 | 121.8 | (66.5-204.4) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 5 | 6.3 | 78.9 | (25.4-184.1) |  |  |  |  |  |  |
| Female | 4 | 2.2 | nc | (nc-nc) |  | Female | 14 | 16.5 | 84.8 | (46.3-142.3) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 22 | 32.3 | 68.1 | (42.7-103.1) |  | Male | 239 | 232.0 | 103.0 | (90.4-117.0) |
| Female | 26 | 35.2 | 73.9 | (48.3-108.3) |  | Female | 251 | 242.6 | 103.5 | (91.1-117.1) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

153

# Kingston

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 12 | 14.3 | 83.9 | (43.3-146.5) |  | Male | 16 | 9.1 | 175.4 | (100.2-284.9) |
| Female | 6 | 5.6 | 106.6 | (38.9-232.0) |  | Female | 10 | 7.5 | 133.5 | (63.9-245.5) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 2 | 2.7 | nc | (nc-nc) |  | Male | 2 | 2.9 | nc | (nc-nc) |
| Female | 4 | 2.4 | nc | (nc-nc) |  | Female | 2 | 2.5 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.5 | nc | (nc-nc) |  | Male | 7 | 8.1 | 86.1 | (34.5-177.4) |
| Female | 51 | 61.8 | 82.5 | (61.5-108.5) |  | Female | 8 | 7.8 | 102.8 | (44.3-202.6) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 5 | 6.7 | 74.1 | (23.9-173.0) |
| Female | 4 | 2.0 | nc | (nc-nc) |  | Female | 4 | 3.2 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 14 | 15.4 | 90.7 | (49.5-152.1) |  |  |  |  |  |  |
| Female | 9 | 16.6 | 54.1 | (24.7-102.7) |  | Female | 2 | 5.2 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 2 | 3.6 | nc | (nc-nc) |  | Male | 12 | 5.1 | 234.3 | (120.9-409.3) |
| Female | 4 | 1.1 | nc | (nc-nc) |  | Female | 9 | 5.7 | 157.0 | (71.6-298.0) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 1.0 | nc | (nc-nc) |  | Male | 41 | 43.0 | 95.3 | (68.3-129.2) |
| Female | 1 | 0.9 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 7 | 7.8 | 89.3 | (35.8-184.1) |  | Male | 5 | 3.5 | 144.0 | (46.4-336.1) |
| Female | 2 | 4.9 | nc | (nc-nc) |  | Female | 1 | 2.3 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 2 | 2.2 | nc | (nc-nc) |  | Male | 3 | 1.8 | nc | (nc-nc) |
| Female | 0 | 0.7 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 9 | 5.8 | 156.3 | (71.3-296.8) |  | Male | 5 | 3.5 | 142.6 | (45.9-332.7) |
| Female | 4 | 4.5 | nc | (nc-nc) |  | Female | 15 | 10.9 | 137.0 | (76.6-226.0) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 1 | 5.1 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 1 | 1.8 | nc | (nc-nc) |  | Female | 15 | 13.3 | 113.2 | (63.3-186.7) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 26 | 25.6 | 101.6 | (66.3-148.8) |  | Male | 183 | 182.9 | 100.1 | (86.1-115.7) |
| Female | 27 | 29.3 | 92.2 | (60.7-134.1) |  | Female | 203 | 207.0 | 98.1 | (85.0-112.5) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

154

# Lakeville

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 10 | 11.5 | 87.0 | (41.7-160.1) |  | Male | 8 | 7.7 | 103.8 | (44.7-204.5) |
| Female | 5 | 3.9 | 127.0 | (40.9-296.4) |  | Female | 4 | 6.0 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 3 | 2.4 | nc | (nc-nc) |  | Male | 3 | 2.5 | nc | (nc-nc) |
| Female | 1 | 2.0 | nc | (nc-nc) |  | Female | 1 | 1.9 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.4 | nc | (nc-nc) |  | Male | 5 | 6.9 | 72.7 | (23.4-169.8) |
| Female | 49 | 50.6 | 96.9 | (71.7-128.1) |  | Female | 5 | 5.8 | 85.6 | (27.6-199.7) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 7 | 6.3 | 111.5 | (44.7-229.6) |
| Female | 1 | 1.7 | nc | (nc-nc) |  | Female | 4 | 2.6 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 10 | 13.0 | 76.9 | (36.8-141.5) |  |  |  |  |  |  |
| Female | 9 | 11.8 | 76.5 | (34.9-145.2) |  | Female | 5 | 4.2 | 117.7 | (37.9-274.6) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 4 | 3.2 | nc | (nc-nc) |  | Male | 2 | 4.3 | nc | (nc-nc) |
| Female | 0 | 0.8 | nc | (nc-nc) |  | Female | 4 | 4.0 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 1 | 0.8 | nc | (nc-nc) |  | Male | 35 | 42.2 | 82.9 | (57.7-115.3) |
| Female | 1 | 0.7 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 5 | 7.2 | 69.5 | (22.4-162.1) |  | Male | 4 | 2.9 | nc | (nc-nc) |
| Female | 2 | 3.9 | nc | (nc-nc) |  | Female | 0 | 1.6 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 2 | 1.9 | nc | (nc-nc) |  | Male | 2 | 1.4 | nc | (nc-nc) |
| Female | 0 | 0.5 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 3 | 4.8 | nc | (nc-nc) |  | Male | 5 | 3.2 | 156.4 | (50.4-364.9) |
| Female | 2 | 3.3 | nc | (nc-nc) |  | Female | 15 | 9.3 | 160.9 | (90.0-265.4) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 4 | 4.5 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 3 | 1.4 | nc | (nc-nc) |  | Female | 13 | 11.7 | 111.6 | (59.4-190.8) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 14 | 21.6 | 64.8 | (35.4-108.8) |  | Male | 139 | 160.5 | 86.6 | (72.8-102.2) |
| Female | 19 | 21.4 | 88.8 | (53.4-138.7) |  | Female | 161 | 161.2 | 99.9 | (85.1-116.6) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

155

# Lancaster

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 7 | 8.2 | 84.9 | (34.0-175.0) |  | Male | 6 | 5.5 | 108.7 | (39.7-236.6) |
| Female | 4 | 2.2 | nc | (nc-nc) |  | Female | 4 | 3.5 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 1 | 1.8 | nc | (nc-nc) |  | Male | 1 | 1.8 | nc | (nc-nc) |
| Female | 0 | 1.1 | nc | (nc-nc) |  | Female | 1 | 1.1 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 1 | 0.3 | nc | (nc-nc) |  | Male | 7 | 5.0 | 141.0 | (56.5-290.6) |
| Female | 28 | 28.2 | 99.5 | (66.1-143.7) |  | Female | 3 | 3.3 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 3 | 4.2 | nc | (nc-nc) |
| Female | 0 | 1.0 | nc | (nc-nc) |  | Female | 0 | 1.4 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 9 | 9.0 | 99.6 | (45.5-189.1) |  |  |  |  |  |  |
| Female | 4 | 6.7 | nc | (nc-nc) |  | Female | 3 | 2.4 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 2 | 2.2 | nc | (nc-nc) |  | Male | 2 | 3.0 | nc | (nc-nc) |
| Female | 0 | 0.5 | nc | (nc-nc) |  | Female | 3 | 2.3 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.9 | nc | (nc-nc) |  | Male | 34 | 28.5 | 119.2 | (82.6-166.6) |
| Female | 0 | 0.5 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 3 | 4.9 | nc | (nc-nc) |  | Male | 0 | 2.0 | nc | (nc-nc) |
| Female | 1 | 2.2 | nc | (nc-nc) |  | Female | 0 | 0.9 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 2 | 1.3 | nc | (nc-nc) |  | Male | 3 | 1.7 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 4 | 3.5 | nc | (nc-nc) |  | Male | 4 | 2.4 | nc | (nc-nc) |
| Female | 3 | 2.0 | nc | (nc-nc) |  | Female | 5 | 5.6 | 90.1 | (29.0-210.2) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 0 | 3.0 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 1 | 0.8 | nc | (nc-nc) |  | Female | 3 | 6.3 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 7 | 15.0 | 46.6 | (18.7-96.0) |  | Male | 100 | 112.9 | 88.6 | (72.1-107.7) |
| Female | 11 | 12.3 | 89.5 | (44.6-160.2) |  | Female | 81 | 91.3 | 88.7 | (70.4-110.3) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

156

# Lanesborough

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 1 | 2.8 | nc | (nc-nc) |  | Male | 5 | 2.0 | 246.4 | (79.4-575.0) |
| Female | 1 | 1.0 | nc | (nc-nc) |  | Female | 2 | 1.5 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 0.7 | nc | (nc-nc) |  | Male | 1 | 0.7 | nc | (nc-nc) |
| Female | 0 | 0.5 | nc | (nc-nc) |  | Female | 0 | 0.5 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 2 | 1.8 | nc | (nc-nc) |
| Female | 11 | 12.5 | 87.9 | (43.8-157.3) |  | Female | 1 | 1.4 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 3 | 1.7 | nc | (nc-nc) |
| Female | 1 | 0.4 | nc | (nc-nc) |  | Female | 0 | 0.6 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 1 | 3.3 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 3 | 3.1 | nc | (nc-nc) |  | Female | 0 | 1.1 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 2 | 0.9 | nc | (nc-nc) |  | Male | 1 | 1.1 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 3 | 1.0 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 1 | 0.3 | nc | (nc-nc) |  | Male | 10 | 11.3 | 88.6 | (42.4-162.9) |
| Female | 0 | 0.2 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 1 | 1.9 | nc | (nc-nc) |  | Male | 1 | 0.7 | nc | (nc-nc) |
| Female | 3 | 1.0 | nc | (nc-nc) |  | Female | 0 | 0.4 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 1 | 0.5 | nc | (nc-nc) |  | Male | 0 | 0.5 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 2 | 1.2 | nc | (nc-nc) |  | Male | 0 | 0.9 | nc | (nc-nc) |
| Female | 2 | 0.8 | nc | (nc-nc) |  | Female | 2 | 2.4 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 0 | 1.2 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 1 | 0.3 | nc | (nc-nc) |  | Female | 2 | 2.7 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 9 | 5.5 | 164.1 | (74.9-311.6) |  | Male | 45 | 42.2 | 106.7 | (77.8-142.8) |
| Female | 3 | 5.3 | nc | (nc-nc) |  | Female | 36 | 40.3 | 89.2 | (62.5-123.5) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

157

# Lawrence

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 54 | 49.4 | 109.4 | (82.2-142.7) |  | Male | 9 | 34.6 | 26.0 | (11.9-49.4) |
| Female | 16 | 19.7 | 81.1 | (46.3-131.7) |  | Female | 9 | 32.8 | 27.4 | (12.5-52.1) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 9 | 12.8 | 70.4 | (32.1-133.7) |  | Male | 11 | 10.7 | 103.2 | (51.5-184.7) |
| Female | 8 | 11.3 | 71.1 | (30.6-140.1) |  | Female | 18 | 9.3 | 193.4 | (114.5-305.6) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 1 | 1.8 | nc | (nc-nc) |  | Male | 21 | 31.3 | 67.1 | (41.5-102.6) |
| Female | 175 | 250.4 | 69.9 | (59.9-81.1) |  | Female | 35 | 29.9 | 117.2 | (81.6-163.0) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 31 | 26.6 | 116.4 | (79.1-165.2) |
| Female | 18 | 9.9 | 182.0 | (107.8-287.7) |  | Female | 12 | 12.8 | 93.5 | (48.2-163.3) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 57 | 57.1 | 99.8 | (75.6-129.3) |  |  |  |  |  |  |
| Female | 44 | 61.3 | 71.8 | (52.2-96.4) |  | Female | 10 | 21.4 | 46.7 | (22.3-85.9) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 8 | 13.4 | 59.6 | (25.7-117.5) |  | Male | 19 | 18.3 | 104.0 | (62.6-162.3) |
| Female | 9 | 3.9 | 230.4 | (105.1-437.4) |  | Female | 14 | 20.3 | 68.8 | (37.6-115.5) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 4 | 6.1 | nc | (nc-nc) |  | Male | 217 | 165.2 | 131.4 | (114.5-150.1) |
| Female | 7 | 5.3 | 132.4 | (53.1-272.9) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 24 | 31.2 | 77.0 | (49.3-114.6) |  | Male | 21 | 12.4 | 168.7 | (104.4-257.9) |
| Female | 24 | 19.3 | 124.6 | (79.8-185.5) |  | Female | 16 | 8.3 | 192.6 | (110.0-312.8) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 10 | 7.9 | 127.0 | (60.8-233.5) |  | Male | 9 | 12.0 | 74.8 | (34.1-142.0) |
| Female | 3 | 2.6 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 16 | 23.4 | 68.3 | (39.0-110.9) |  | Male | 14 | 16.4 | 85.6 | (46.8-143.7) |
| Female | 19 | 18.8 | 101.3 | (60.9-158.1) |  | Female | 62 | 56.7 | 109.4 | (83.9-140.2) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 37 | 19.0 | 195.0 | (137.3-268.8) |  |  |  |  |  |  |
| Female | 14 | 6.8 | 205.1 | (112.0-344.2) |  | Female | 49 | 54.5 | 89.9 | (66.5-118.8) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 92 | 89.4 | 102.9 | (83.0-126.2) |  | Male | 723 | 694.7 | 104.1 | (96.6-111.9) |
| Female | 97 | 103.4 | 93.8 | (76.1-114.5) |  | Female | 716 | 823.3 | 87.0 | (80.7-93.6) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

158

# Lee

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 15 | 9.1 | 165.3 | (92.4-272.6) |  | Male | 6 | 5.3 | 113.1 | (41.3-246.1) |
| Female | 1 | 2.6 | nc | (nc-nc) |  | Female | 6 | 3.5 | 172.3 | (62.9-374.9) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 2 | 1.5 | nc | (nc-nc) |  | Male | 1 | 1.8 | nc | (nc-nc) |
| Female | 5 | 1.1 | 438.5 | (141.3-1023.3) |  | Female | 0 | 1.2 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  | Male | 2 | 4.7 | nc | (nc-nc) |
| Female | 26 | 28.9 | 89.9 | (58.7-131.7) |  | Female | 3 | 3.6 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 2 | 3.8 | nc | (nc-nc) |
| Female | 1 | 0.9 | nc | (nc-nc) |  | Female | 2 | 1.5 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 6 | 9.0 | 67.0 | (24.5-145.9) |  |  |  |  |  |  |
| Female | 6 | 7.2 | 83.7 | (30.6-182.1) |  | Female | 2 | 2.5 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 5 | 2.3 | 222.1 | (71.6-518.4) |  | Male | 3 | 3.1 | nc | (nc-nc) |
| Female | 1 | 0.5 | nc | (nc-nc) |  | Female | 1 | 2.6 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 1 | 0.5 | nc | (nc-nc) |  | Male | 20 | 27.1 | 73.8 | (45.1-114.1) |
| Female | 0 | 0.4 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 5 | 4.5 | 111.5 | (35.9-260.2) |  | Male | 0 | 2.1 | nc | (nc-nc) |
| Female | 4 | 2.3 | nc | (nc-nc) |  | Female | 4 | 1.0 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 2 | 1.3 | nc | (nc-nc) |  | Male | 1 | 0.9 | nc | (nc-nc) |
| Female | 1 | 0.3 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 2 | 3.4 | nc | (nc-nc) |  | Male | 4 | 1.8 | nc | (nc-nc) |
| Female | 1 | 2.0 | nc | (nc-nc) |  | Female | 3 | 4.9 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 2 | 2.9 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 1 | 0.9 | nc | (nc-nc) |  | Female | 5 | 6.8 | 73.9 | (23.8-172.5) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 19 | 16.1 | 118.2 | (71.2-184.7) |  | Male | 107 | 110.0 | 97.2 | (79.7-117.5) |
| Female | 18 | 14.3 | 125.9 | (74.6-199.1) |  | Female | 97 | 96.8 | 100.2 | (81.3-122.2) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

159

# Leicester

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 12 | 12.0 | 100.4 | (51.8-175.4) |  | Male | 14 | 7.8 | 178.4 | (97.4-299.3) |
| Female | 5 | 4.8 | 104.9 | (33.8-244.8) |  | Female | 7 | 6.4 | 109.0 | (43.7-224.5) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 2 | 2.4 | nc | (nc-nc) |  | Male | 3 | 2.6 | nc | (nc-nc) |
| Female | 2 | 2.0 | nc | (nc-nc) |  | Female | 2 | 2.2 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 1 | 0.4 | nc | (nc-nc) |  | Male | 2 | 7.0 | nc | (nc-nc) |
| Female | 43 | 52.5 | 81.9 | (59.3-110.3) |  | Female | 4 | 6.6 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 8 | 6.0 | 132.3 | (57.0-260.8) |
| Female | 4 | 1.7 | nc | (nc-nc) |  | Female | 3 | 2.8 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 11 | 13.2 | 83.6 | (41.7-149.6) |  |  |  |  |  |  |
| Female | 7 | 13.6 | 51.6 | (20.7-106.2) |  | Female | 6 | 4.6 | 131.9 | (48.2-287.0) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 5 | 3.2 | 154.8 | (49.9-361.4) |  | Male | 1 | 4.3 | nc | (nc-nc) |
| Female | 0 | 0.9 | nc | (nc-nc) |  | Female | 4 | 4.7 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 1.0 | nc | (nc-nc) |  | Male | 29 | 40.0 | 72.4 | (48.5-104.0) |
| Female | 1 | 0.8 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 5 | 7.0 | 71.4 | (23.0-166.6) |  | Male | 2 | 2.9 | nc | (nc-nc) |
| Female | 6 | 4.2 | 141.6 | (51.7-308.1) |  | Female | 0 | 1.8 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 2 | 1.9 | nc | (nc-nc) |  | Male | 1 | 1.7 | nc | (nc-nc) |
| Female | 0 | 0.6 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 12 | 4.9 | 244.5 | (126.2-427.1) |  | Male | 4 | 3.2 | nc | (nc-nc) |
| Female | 5 | 3.7 | 135.5 | (43.7-316.1) |  | Female | 5 | 9.3 | 53.5 | (17.3-124.9) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 1 | 4.5 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 1.6 | nc | (nc-nc) |  | Female | 13 | 12.0 | 108.7 | (57.8-185.8) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 17 | 21.8 | 77.8 | (45.3-124.7) |  | Male | 144 | 160.5 | 89.7 | (75.6-105.6) |
| Female | 19 | 25.7 | 73.9 | (44.4-115.3) |  | Female | 148 | 176.4 | 83.9 | (70.9-98.5) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

160

# Lenox

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 17 | 11.3 | 150.1 | (87.4-240.3) |  | Male | 8 | 6.0 | 133.4 | (57.5-262.9) |
| Female | 2 | 3.9 | nc | (nc-nc) |  | Female | 6 | 4.1 | 146.4 | (53.4-318.6) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 1 | 1.5 | nc | (nc-nc) |  | Male | 3 | 2.0 | nc | (nc-nc) |
| Female | 2 | 1.3 | nc | (nc-nc) |  | Female | 1 | 1.7 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  | Male | 6 | 5.4 | 110.9 | (40.5-241.3) |
| Female | 38 | 33.5 | 113.4 | (80.3-155.7) |  | Female | 4 | 4.9 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 3 | 3.8 | nc | (nc-nc) |
| Female | 0 | 0.8 | nc | (nc-nc) |  | Female | 2 | 2.0 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 15 | 10.6 | 141.6 | (79.2-233.6) |  |  |  |  |  |  |
| Female | 16 | 10.9 | 146.3 | (83.6-237.7) |  | Female | 6 | 3.0 | 198.1 | (72.3-431.1) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 1 | 2.5 | nc | (nc-nc) |  | Male | 3 | 3.7 | nc | (nc-nc) |
| Female | 0 | 0.7 | nc | (nc-nc) |  | Female | 5 | 4.1 | 122.0 | (39.3-284.7) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 1 | 0.4 | nc | (nc-nc) |  | Male | 24 | 27.6 | 86.9 | (55.7-129.4) |
| Female | 0 | 0.3 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 5 | 4.6 | 108.3 | (34.9-252.7) |  | Male | 0 | 2.5 | nc | (nc-nc) |
| Female | 3 | 2.9 | nc | (nc-nc) |  | Female | 0 | 1.5 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 1.3 | nc | (nc-nc) |  | Male | 0 | 0.5 | nc | (nc-nc) |
| Female | 0 | 0.4 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 2 | 3.9 | nc | (nc-nc) |  | Male | 0 | 1.6 | nc | (nc-nc) |
| Female | 2 | 2.8 | nc | (nc-nc) |  | Female | 2 | 4.3 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 2 | 3.0 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 1.2 | nc | (nc-nc) |  | Female | 7 | 7.7 | 90.6 | (36.3-186.7) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 12 | 18.5 | 65.0 | (33.5-113.5) |  | Male | 110 | 122.1 | 90.1 | (74.1-108.6) |
| Female | 18 | 19.3 | 93.5 | (55.4-147.7) |  | Female | 127 | 122.7 | 103.5 | (86.3-123.2) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

161

# Leominster

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 60 | 46.9 | 127.9 | (97.6-164.7) |  | Male | 22 | 29.5 | 74.6 | (46.7-112.9) |
| Female | 28 | 15.2 | 183.7 | (122.0-265.5) |  | Female | 17 | 21.8 | 78.0 | (45.4-124.9) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 5 | 8.7 | 57.3 | (18.5-133.6) |  | Male | 11 | 9.5 | 116.2 | (57.9-208.0) |
| Female | 8 | 6.9 | 115.2 | (49.6-227.1) |  | Female | 4 | 7.0 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 2 | 1.6 | nc | (nc-nc) |  | Male | 24 | 26.5 | 90.5 | (57.9-134.6) |
| Female | 176 | 173.7 | 101.3 | (86.9-117.5) |  | Female | 24 | 21.6 | 110.9 | (71.0-165.0) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 22 | 21.5 | 102.2 | (64.0-154.8) |
| Female | 9 | 6.0 | 149.2 | (68.1-283.3) |  | Female | 10 | 9.2 | 109.1 | (52.2-200.7) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 43 | 50.8 | 84.7 | (61.3-114.1) |  |  |  |  |  |  |
| Female | 33 | 46.0 | 71.8 | (49.4-100.8) |  | Female | 30 | 14.9 | 200.8 | (135.5-286.7) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 13 | 11.7 | 111.0 | (59.0-189.8) |  | Male | 13 | 16.5 | 78.7 | (41.9-134.6) |
| Female | 3 | 2.9 | nc | (nc-nc) |  | Female | 17 | 15.6 | 109.1 | (63.5-174.6) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 1 | 3.5 | nc | (nc-nc) |  | Male | 136 | 137.6 | 98.8 | (82.9-116.9) |
| Female | 3 | 2.8 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 30 | 25.3 | 118.6 | (80.0-169.3) |  | Male | 13 | 11.2 | 115.6 | (61.5-197.7) |
| Female | 14 | 13.7 | 102.5 | (56.0-172.0) |  | Female | 2 | 6.2 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 9 | 6.8 | 133.3 | (60.8-253.0) |  | Male | 3 | 6.3 | nc | (nc-nc) |
| Female | 0 | 1.9 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 17 | 18.8 | 90.6 | (52.7-145.1) |  | Male | 12 | 11.6 | 103.4 | (53.3-180.5) |
| Female | 12 | 12.7 | 94.6 | (48.8-165.3) |  | Female | 23 | 33.5 | 68.7 | (43.6-103.2) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 7 | 15.8 | 44.4 | (17.8-91.5) |  |  |  |  |  |  |
| Female | 3 | 5.0 | nc | (nc-nc) |  | Female | 43 | 38.1 | 113.0 | (81.8-152.2) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 79 | 81.4 | 97.0 | (76.8-120.9) |  | Male | 559 | 590.8 | 94.6 | (86.9-102.8) |
| Female | 90 | 79.4 | 113.3 | (91.1-139.3) |  | Female | 597 | 581.1 | 102.7 | (94.7-111.3) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

162